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 High mobility group A2 (HMGA2) is a non-histone protein highly expressed 
during the development, but is low or absent in most adult tissues. Epithelial-
mesenchymal transition (EMT) plays a critical role in prostate cancer progression and 
metastasis. HMGA2 has been shown to promote EMT in separate studies. Interestingly, 
wild-type HMGA2 and truncated (lacking the 3’UTR) HMGA2 isoforms are 
overexpressed in many cancers. However, there are no studies on the role of each isoform 
in prostate cancer progression. We hypothesized that wild-type and truncated HMGA2 
promotes prostate cancer progression by different mechanisms. We analyzed the 
expression of HMGA2 in the prostate panel by western blot analysis and the localization 
in prostate tissue microarray by immunohistochemistry. We stably overexpressed wild-
type and truncated HMGA2 cDNA in LNCaP cells and measured the expression and the 
localization of HMGA2 as well as EMT markers. We also performed migration and cell 
viability assays.  
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 We analyzed phospho-ERK in cells overexpressing HMGA2 as well as inhibition 
with U0126 (MAPK inhibitor). To explore the role of truncated HMGA2, we measured 
the reactive oxygen species (ROS) concentration by DCFDA dye, as well as analyzing 
Jun-D as a putative downstream effector of HMGA2. Additionally, we knocked down 
Jun-D and performed migration and cell viability assays. We treated ARCaP-M 
mesenchymal cells with camalexin, a 3-thizol-2-yl-indole (a natural product, as a 
candidate to target HMGA2) in vitro and in vivo in nude mice. Our results showed an 
increase in nuclear HMGA2 expression with prostate cancer progression as compared to 
normal tissue. LNCaP cells overexpressing wild-type but not truncated HMGA2 
displayed nuclear localization and induced EMT via ERK1/2 pathway, and this effect 
could be reversed by treating the cells with U0126. Conversely, truncated HMGA2 
displayed cytoplasmic expression and increased prostate cancer migration via increasing 
Jun-D expression and ROS; this could be antagonized by Jun-D knockdown. Finally, 
treating ARCaP-M aggressive prostate cancer cells with camalexin reduce its expression 
in vitro and in vivo. In conclusion, both wild-type and truncated HMGA2 induce prostate 
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Prostate cancer (PCa) is considered the second leading of death in American men 
with estimates of 164,690 new cases and 29,430 death incidence in the United State for 
2018.1 Compared with other cancers, prostate cancer is a slow growing cancer. Although 
the main cause of prostate cancer is unknown, there are many risk factors associated with 
prostate cancer such as age, diet,2 family history,3 and race.4 Around 90% of older men 
have an enlarged prostate; this condition is known as benign prostatic hyperplasia5 
(BPH). Anatomically, BPH mainly affects the transition zone in the prostate gland, while 
70-80% cases of PCa raised in the peripheral zone.6 Epidemiological studies have shown 
that there are 83.3% cases of PCa that are associated with BPH.7 
African American men have the highest incidence and mortality rate of prostate 
cancer compared to other races.8 Normal prostate cells can undergo transformations 
which make the cells grow without control, leading to prostate cancer. In the late stage of 
prostate cancer, the tumor can migrate or metastasize into distant organs through the 
bloodstream and the lymph system. Epithelial-mesenchymal transition (EMT) plays a 
critical role in cancer progression and metastasis. 
Normal epithelial tissues are characterized by strong interaction between cells 




cells. That connection allows the actin cytoskeleton, gap junctions and the intermediate 
filament skeleton to tightly regulate cellular signaling and keep the tissue intact. During 
cancer progression, that cellular rhythm can be disrupted, and the epithelial cells can 
undergo morphological and biochemical changes(EMT) to form a new phenotype of 
mesenchymal cells.9 EMT is characterized by downregulation of epithelial-associated 
gene such as E-cadherin and occludins,10 and upregulation of mesenchymal genes such as 
vimentin and N-cadherin.11 
HMGA2 is a non-histone protein. HMGA gene family contains four proteins; 
HMGA1a, HMGA1b, HMGA1c and HMGA2.12 HMGA proteins are alternatively 
spliced variants of the same gene to generate the four proteins. HMGA gene contains 3 
basic repeat domains in the amino terminal known as AT hooks, which can bind to DNA 
in order to contribute to transcriptional activity of many genes by repositioning 
chromatin.13 HMGA has an important role in development and cell growth and is highly 
expressed during the embryogenesis, whereas the gene expression is very low or absent 
in adults.14 A recent study has shown that HMGA2 can up-regulate Snail following TGF-
β stimulation, by co-association with SMAD3/4 to Snail promoter, thereby inducing 
EMT.15 Due to unknown mechanisms of chromosomal 12 rearrangements where 
HMGA2 gene is located, post-transcriptional deletion of 3’ untranslated region (3’UTR) 
of the gene can give rise to a truncated isoform.16 
Reactive Oxygen Species (ROS) are free radical molecules found in all aerobic 
organisms. Normal concentrations of ROS are required for cellular functions such as, cell 




ROS to induce the metabolic activity, mitochondrial dysfunction and cell signaling 
deregulation.18 Accumulation of ROS in cancer cells leads to activation of different 
transcription factors, such as nuclear factor-κB (NF-κb)and Snail in order to mediate 
EMT.19 AP-1 (activating protein-1) transcription factor is involved in regulating cell 
proliferation, survival and cell death.20AP-1 proteins are composed of Jun (c-Jun, Jun-B 
and Jun-D) and Fos (c-Fos, FosB, Fra-1and Fra-2).21  It has been shown that Jun-D 
induces ROS production in response to androgen in prostate cancer cells.22 We have 
previously shown that camalexin, a natural product found in cruciferous vegetables, can 
antagonize aggressive prostate cancer cells via ROS.23 
Interestingly, wild-type HMGA2 and truncated (lacking the 3’UTR) HMGA2 
isoform are overexpressed in several benign tumors such as lipomas, uterine leiomyomas, 
pleomorphic adenoma of the salivary glands, and hematomas of breast and lung.24 
However, there are no reports of HMGA2 expression in prostate patient tissue or studies 
investigating the differential function of each isoform in prostate cancer. The goal of this 
study was to investigate the role of HMGA2 in prostate cancer progression, with 
emphasis on the differential function of wild-type vs truncated isoforms. Another novelty 
of the study was using camalexin, a natural product, as a potential to target HMGA2 in 
prostate cancer. We hypothesized that overexpression of wild-type and/or truncated 
isoform of HMGA2 will promote prostate cancer progression by differential 
mechanism(s) and may be antagonized by camalexin. The following specific aims were 




 Specific Aim 1: Characterize the wild-type and truncated isoforms of HMGA2 in 
prostate cancer.  
 Recent studies have reported overexpression of HMGA2 protein in malignant 
phenotype cancers including increased HMGA2 mRNA in a canine prostate cancer 
model.25 Our preliminary data showed that HMGA2 is highly expressed in aggressive 
prostate cancer cell lines, and displays nuclear localization in mesenchymal cells, and 
cytoplasmic in epithelial cells. We did the following: 
1. determined the expression and localization of HMGA2 in prostate patient 
tissue.  
2. stably overexpressed HMGA2 wild-type (WT) and truncated (TR) isoform in 
LNCaP cells that express low level of HMGA2. 
3. determined the mRNA and Protein expression of HMGA2 in LNCaP cells 
stably overexpressing wild-type (WT) or truncated (TR) HMGA2 cDNA. 
 Specific Aim 2: Investigate the function of both wild-type (WT) and truncated 
 (TR) HMGA2 in prostate cancer. 
 HMGA2 has been found to play a direct role to induce EMT in malignant cancer 
following activation of TGF-β signaling.15 Although, both HMGA2 wild-type and 
truncated have been upregulated in cancer, it has never been confirmed which isoform 
contributes to EMT, and whether they have differential functions. In this aim, we utilized 
the LNCaP cell lines developed in Aim 1 to investigate the individual role for WT vs TR 




 1. determined whether overexpression of WT or TR HMGA2 will induce EMT  
  in prostate cancer cell lines and the signaling mechanism(s) involved.  
2. determined if overexpression of WT or TR HMGA2 promotes cell migration 
and/or proliferation in prostate cancer. 
3. determined whether ROS is involved in the function of WT or TR HMGA2. 
4. utilized proteomics to further delineate the differential roles of WT vs TR 
HMGA2. 
 Specific Aim 3: Determine if HMGA2 signalling can be antagonized by 
 camalexin. 
 Camalexin is a 3-indole phytoalexin that accumulates in various cruciferous 
plants in response to plant pathogen attack or abiotic stress (e.g., cauliflower, cabbage, 
and broccoli).26 Previously, we showed that treating prostate cancer with camalexin 
induces apoptosis via increasing the levels of ROS.27 To investigate whether camalexin 
can antagonize HMGA2 signaling, we did the following: 
1. determined if Camalexin affects the expression of HMGA2 in vitro. 










2.1 Prostate Gland  
The prostate gland is an exocrine gland that is part of the reproductive system in 
the male. It is walnut size and located below the bladder and surrounds the urethra, the 
tube that carries urine and semen out the body. The main function of the prostate gland is 
to secrete an alkaline fluid which carries the sperms.    
Morphological anatomy for the prostate gland in human adults was classified by 
McNeal et al. into three main zones: transition zone, central zone, and peripheral zone29 














The transition zone spans from the bladder neck to the membranous urethra; it is 
also called prostatic urethra.30 The transition zone consists of epithelial tissues which 
usually enlarge with age. The benign hyperplasia in prostate gland takes place in this 
zone which can cause bladder obstruction. The transition zone is covered with 
approximately 10% of glandular tissue and 20% adenocarcinomas occur in this zone.31 
The central zone lies behind the transition zone and is surrounded by the ejaculatory 
ducts which run from the seminal vesicle to the urethra. 25% of this zone consists of 
glandular tissues, however, the adenocarcinomas occur in only 1-5% in this zone, which 
means prostate cancer rarely occurs there, though when it does, the cancer can develop 
into very aggressive cancer.32 The peripheral zone is the largest zone in the prostate 
gland, 70% of adenocarcinoma occurs in this area, which makes the most chronic 
prostate cancer occurrence in the peripheral zone.33 
The formation of the prostate like the other tissues starts during the interaction 
between the epithelium and the mesenchymal tissues. The rudimentary prostate in human 
embryos starts to appear as a small epithelial bud at the urogenital sinus (UGS) in the 
Mullerian tubercle. Under the mesenchymal control, the buds form a solid branching cord 
which gives rise to the lumen by the birth. The formation of the lumen followed by apical 
cell polarization, starts prostate activity.34 The prostate gland also contains stroma which 
mainly forms the smooth muscles, the ducts and acini lining the epithelium layer and the 
lumen with the secretory epithelium.35 The stromal prostate tissues are composed of 
blood vessels, nerves, fibroblasts, and diverse infiltrate immune and inflammatory cells. 




receptors (ARs) by androgens. Different rat studies give evidence to the high expression 
of AR during early stage development within mesenchymal cells of UGS, during the 
creation of prostate buds.36 AR plays a role in regulating proliferation and differentiation, 
in collaboration with other paracrine signaling molecules such as epidermal growth factor 
(EGF), fibroblast growth factor (FGF), and insulin-like growth factor (IGF).37 Studies 
showed that transgenic mice with stromal AR knockdown have suppressed prostate 
growth.38 Androgen function is involved in testicular synthesis of testosterone and also 
plays a role in conversion of testosterone into its active form, 5α-dihydrotestosterone 
(DHT), which bind to AR.39 AR homdimerizes and is phosphorylated before its 
translocation into the nucleus where it can bind to androgen response elements (AREs) 
on DNA to increase prostate specific-antigen (PSA) levels, cells proliferation, and 
differentiation (see Figure 2). Around 80-90% of prostate cancer patients are diagnosed 
with malfunction in androgen signaling either by decreased androgen secretion in the 













2.2 Prostate Cancer 
Prostate cancer is the most common type of cancer diagnosed and the second 
leading cause of death in men.42 Prostate cancer is a very slow progression disease; old 
men may die without knowing they had prostate cancer.43 There are many risk factors 
that contribute to the occurrence or the progression of prostate cancer; these factors 
include age, family history, and race.4 Eighty percentage of old men aged >50 showed 
evidence of prostate cancer.44  Moreover, recent studies have included nutrition and 
environmental factors as risk factors.45 Prostate cancer forms by uncontrolled cell 
proliferation and inhibition of apoptosis leading to a tumor growth within the prostatic 
epithelial tissue.46 
 
2.3 Prostate Cancer Diagnosis and Grades  
Physicians use a combination of different markers including PSA, clinical stages, 
and Gleason score to detect the extent of this cancer type.47 After prostate cancer is 
diagnosed by biopsy, clinically, the cancer can be described with different stages based 
on the cancer location and how far the cancer cells have spread from the prostate gland. 
 In the early stage I, the abnormal cells start to appear in prostate gland without 
spreading to nearby tissue, along with rise in prostate-specific antigen (PSA). In stages II 
and III, the number of cancer cells increase and the prostate gland is enlarged, with 
spreading of cancer cells into nearby tissues and organs such as lymph node or seminal 
vesicles. By the last stage IV, the cancer cells migrate to the distant parts of the body 




with many patients. However, the late diagnosed stages of prostate cancer show increased 
resistance to treatment.49 
Classification of prostate cancer can also be based on TNM system; T refers to 
tumor size and N to the number of lymph nodes that have cancer, while M refers to 
whether the cancer has metastasized into different organs.50 The pathologist gives the 
tumor grade based on microscopy examination of the abnormal morphology and the 
migration of cancer cells into different part of the body. 
Gleason system of scoring a biopsy from the cancer is compared with healthy 
tissue. The degree of differences is the criteria for grading in the scale of 3 to 5. The 
appearances of aggressive tumor tissues when compared to healthy tissues will get a 
higher Gleason score. The tissues are viewed and compared for two different areas of 
growth and two different scores are allotted. These scores are added to get a final score 
between 6 and 10. The score 6 indicates a less aggressive tumor whereas a higher value 
of 10 shows the presence of a more aggressive tumor.51 The Gleason scores in the scale 
of 6-10 are often graded in five groups (1 to 5). A score of 6 will be a part of group1 and 
a score 10 will form a part of group 5. The Gleason score is very important to identify the 
behavior of the prostate cancer and to provide appropriate medication.52 
 
2.4 Castration Resistant Prostate Cancer (CRPC) 
CRPC is an untreatable stage of prostate cancer; patients in this stage 
characterized by increase the aggressiveness their disease progression after surgical or 
androgen deprivation.53 It is still not clear how the prostate cancer cells undergo in 




this stage are very limited, which lead the tumor develop metastasis mainly into bone. 
Patients with this complication have mean survival time around 1-2 years.53 In order for 
the physicians to identify individuals with CRPC, they consider different factors such as 
serum castration of testosterone, PSA, and AR.55 
 
2.5 Prostate Cancer and Bone Metastasis  
Cancer metastasis occurs during the late stages of cancer, when the cells start 
separating from the primary location and form a new tumor in different organs. 70-80% 
of prostate cancer patients are diagnosed with cancer metastases into lymph nodes and 
bone.56 Prostate cancer has been reported to metastasize into sternum, pelvic bone, ribs 
and femurs.57 Metastasis in different carcinoma into bone for instance lung, breast, and 
thyroid cancers usually cause degradation of bone and are termed “osteolytic.”58-59 In 
contrast, prostate cancer bone metastasis causes bone formation and is called 
“osteoblastic.”60  However, the actual mechanisms of prostate cancer metastasis to the 
bone are still not well known. Paget suggested that the metastatic cancer cells were 
enhanced selectively based on appropriate environments; this phenomena was described 
as “seed-and-soil.”61 
The metastatic process takes place following several steps, starting with the 
primary tumor inducing angiogenesis to supply the cancer cells with oxygen in blood and 
required growth factors. The increased tumor size is followed by the breakdown of the 
extracellular matrix (ECM) which allows the tumor cells to intravasate into the blood 
vessels. Cells subsequently lose their cell-cell adhesion, and start to migrate or 




as the seed) selects the new host organ (which he called to the soil) based on many 
factors.63 
Normally, the balance between the osteoclasts (bone resorption) and osteoblasts 
(bone formation) is important to keep homeostasis in bone tissue. Prostate cancer patients 
display elevated serum levels of osteoblats proliferation markers, alkaline phosphate 
andtype I procollagen C-propetide.64 Stimulation of bone resorption is also observed in 
prostate cancer patients, although osteoblastogenesis supersedes osteoclastogenesis 
leading to more bone formation at the bone metastatic site.60 The osteclast cells express 
local factors such as receptor activator of nuclear factors-κ B ligand (RANKL), IL1, IL6, 
IL17.65 However, proliferation and differentiation of osteoblasts includes releasing of 
parathyroid hormone, prostaglandins, transforming growth factor-β (TGF-β), and insulin 
growth factors (IGF).66 PSA and urokinase-type plasminogen activator (uPA) have role in 
modifying the bone environment through activation the TGF-β and stimulating the 
osteoblast cell proliferation.67 
 
2.6 Prostate Cancer Treatment 
The treatment options for prostate cancer are mainly through hormone control, 
chemotherapy, or removing the prostate gland by surgery (prostatectomy).  
 2.6.1 The Hormonal Therapy  
 The Hormonal therapy is usually done by suppressing the levels of androgens or 
inhibiting the interaction of androgen with AR. The concept of androgen suppression to 
control prostate diseases was discovered when Huggins and Clarence Hodges monitored 




with either castration or oestrogen therapy (which counters the effect of testosterone). 
The study suggested that prostate cancer is enhanced by the androgen activity in the body 
which can be a possible therapeutic target for advanced prostate cancer patients.68 There 
are multiple ways to regulate androgen secretions; for example, androgen secretion can 
be regulated by luteinizing hormone (LH)-releasing hormone (LHRH) which is secreted 
from the pituitary gland. In the prostate gland LHRH binds with dihydrotesterone (DHT) 
and testosterone to activate target genes.69 A trial III  phase study using a combination of 
androgen suppression and irradiation plus an analogue of LHRH in prostate cancer 
patients increased disease-free and overall survival.70 In high-grade cases (Gleason score 
>8), the testicles are surgically removed (castration) in addition to lowering of the 
androgen levels. 
 2.6.2 Testosterone Replacement Therapy (TRT)  
 TRT is another hormone control used after the radical prostatectomy. Pastuzak et 
al. conducted a large study using hypogonadism with testosterone replacement therapy in 
103 men with follow-up for 27.5 months after prostatectomy to control the symptoms and 
signs of their conditions. The study showed a significant increase in PSA levels which 
supported the efficiency of TRT.71 
 2.6.3 Chemotherapy  
 Chemotherapy drugs can target the rapidly dividing cancer cells and affect the 
growth of cancer to delay symptoms. Chemotherapy is used to treat both advanced 
prostate cancer (metastatic) as well as local prostate cancer. Some drugs such as 




Nilutamide shows effectiveness in advanced metastatic prostate cancer.73 Docetaxel, 
Cabazitaxel, Mitoxantrone, Estramustine, and Doxorubicin are some of the commonly 
used chemotherapeutic drugs.74 
 2.6.4 Prostatectomy  
 Prostatectomy is a surgical removal of partial or complete prostate gland and the 
surrounding tissue.75 Before the surgery is performed, the doctors perform a biopsy and 
check the PSA levels for the patient to make sure the cancer has not spread.      
 
2.7 Natural Products for Treatment of Prostate Cancer 
 Many studies showed the direct association of EMT with cancer therapy 
resistance. Additionally, androgen ablation in the hormonal therapy of prostate cancer 
increased the selection for neuroendocrine differentiation which leads to resistance to 
therapy.76 In pancreatic cancer the activation of Notch signaling pathway induces EMT 
and increase the chemoresistance in metastatic pancreatic cancer.77 Tumor cells and the 
surrounding environmental interactions are one of the biggest challenges that contribute 
to therapyresistance.78  
 Doxorubicin for example, is a chemotherapy used to induce apoptosis in response 
to cellular damage in cells, however, a specific mutation in p53 gene in cancer cells leads 
to the resistance of doxorubicin therapy in breast cancer.79 Doxorubicin shows  
sufficient treatment for non-metastatic prostate cancer,80 but its shows resistance in  
castration-resistant prostate cancer (CRPC).81 Therefore, one of the mechanisms to 




shown previously the effect of muscadine grape skin extract (MSKE) as an antioxidant in 
antagonizing EMT in both prostate and breast cancer.82 
 Phytoalexins are a group of natural products produced by plants in response to 
pathogen infection and various antibiotics.83 Camalexin (3-thiazol-2’-yl-indole) is a 
phytoalexin present in cruciferous vegetables that has been demonstrated to have an 
effect on cancer cells by increasing apoptosis and decreasing cell viability in vitro.83 In 
addition to increased apoptosis, Camalexin has no effect on healthy and normal epithelial 
cells, but is more effective in highly aggressive tumor cells. Camalexin destroys the 
affected cells that already produce high reactive oxygen species (ROS), by generating 
even higher levels of ROS, which leads to increase apoptosis in vitro.23 
 
2.8 Epithelial-Mesenchymal Transition   
 Typically the normal epithelial cells are a single layer, with consistent range, and 
evenly spaced between cell-cell junctions. Additionally, adherent proteins between the 
epithelial cells hold the cells tightly and prevent the mobilization of the cells from the 
monolayer sheet.84 During cancer progression, the epithelial cells can undergo 
physiological changes make them polarized which allows the cells to change their 
phenotype and degrade the ECM to lose the tightness junction between the cells.85 This 
transition known as epithelial-mesenchymal transition or EMT leads to these epithelial 
cells becoming mesenchymal cells with irregular and spindle shapes.86 The junction’s 
proteins between the mesenchymal cells are down-regulated, which leads to loss of cell-




ability of the epithelial to mesenchymal cells was first described by Elizabeth Hey 
(Harvard University, Boston, MA).88 
In normal cells EMT process is essential to the embryonic development, but 
cancer cells have hijacked this process to utilize the same developmental mechanisms 
during the tumor progression.89 EMT is associated with downregulation of epithelial 
molecular markers such as E-cadherin and occludin, while the mesenchymal markers 







Figure 3. Epithelial to mesenchymal transition (EMT).90 
 
2.9 Signaling Pathways that Promote EMT in Prostate Cancer 
The progression of epithelial cells into mesenchymal phenotype in cancer is one 
of the most important steps for metastasis. It allows tumor cells to leave the primary 
organ, and migrate to new environments in distant organs.91 The EMT process has been 
reported as the initial step to establish the migration and metastasis in many cancers such 
as breast,92 ovarian carcinoma,93 lung,94 and prostate cancers.95 During the EMT 
transition the benign tumor in the primary organ starts to infiltrate surrounding the tissue 




directly and indirectly by multiple molecular mechanisms. These include growth factor 
signaling pathways such as TGF-β, Endothelial growth factor (EGF), IGF-1, Mitogen-
activated protein kinases (MAPKs), and Fibroblast growth factors (FGF)as well as many 
extracellular signaling regulators such as Wnt pathway, and many transcription factors 









Figure 4. Different signaling pathways promote EMT.96 
 
 TGF-β is a large family that consists of TGF-βs, activins, inhibins, bone 
morphogenetic proteins (BMPs), and Mullerian-inhibiting substance.90 TGF-β has three 
isoforms; TGF-β1, TGF-β2, and TGF-β3, and is expressed during the development. 
However, the expression of TGF-β1 is associated with EMT during wound healing, 
fibrosis, and cancers.97 The role of TGF-β signaling to induce the EMT has been studied 
using BMP-7, an endogenous inhibitor of TGF-β signaling.98 Re-establishing BMP-7 
levels led to up-regulation of E-cadherin, cytokeratin 5/8 (CK5/8) levels, and down-




In non-transformed prostate hyperplasia cells, EMT was induced by TGF-β via 
activation of SMAD signaling and increased levels of Slug and ZEB1 transcription 
factors.100 Another study showed the role of TGF-β in breast cancer model via Nuclear 
Factor Kappa B (NF-κB) to induce EMT and metastasis. Blocking NF-κB signaling 
prevented epithelial cells’ transformation and reverser of EMT.101 In prostate cancer 
however, EMT programming can be induced by androgens through activation of Snail 
and that function can possibly bypass TGF-B signaling.102 Further evidence showed that 
STAT3 expression is induced by TGF-B which mediates transcription factor TWIST1, in 
order to promote EMT in prostate cancer cells.103 Up-regulating prostate apoptosis 
response-4 (PAR-4) by TGF-β signaling increased Snail and Vimentin, as well as 
induction of migration in prostate cancer cells.104 
MAPKs are highly conserved cascade protein kinases. These proteins are 
activated by phosphorylation of serine and threonine residues. MAPK family is involved 
in many cellular processes such as proliferation, differentiation, cell motility, stress 
response, survival, and apoptosis.105 The MAPK family includes extracellular regulator 
kinase 1and 2 (ERK1/2), JNK, and p38 kinase. They signal by phosphorylation which 
activates them leading to translocation of MAPKs into nucleus, which subsequently 
modulates different transcription factors. It has been reported that in breast cancer, Snail 
and phospho-ERK1/2 are upregulated. The study also demonstrated the role of Snail in 
regulating ERK which lead to EMT and increased cell migration.106 Another study 
showed the role of TGF-β in mediating ERK phosphorylation to induce EMT and p38 




EMT.107  However, inhibiting the MAPK pathway using U0126 inhibited the 
phosphorylation of ERK and blocked TGF-β1-mediated EMT by restoring E-cadherin 
expression at cell-cell junctions.108 
 
2.10 High Mobility Group (HMG) Proteins 
High mobility group (HMG) is a non-histone protein. HMG superfamily contains 
three proteins; HMGA, HMGB, and HMGN (see Figure 5). All HMGs contain the amino 
terminal and carboxyl terminal with a unique motif for each family member. They can 
bind with DNA and chromatin in order to contribute to transcriptional activity of many 
genes.HMG proteins do not have transcriptional activities; however, they can bind with 
transcription factors to alter the chromatin structure, which leads to up-regulation or 
down-regulation of different genes. The clear mechanism(s) of how HMG proteins can 





Figure 5. The main structure of HMG protein families.110 
 
HMG protein is highly expressed during the embryogenesis, whereas the gene 
expression is very low or absent during adulthood. This gene has an important role in 
development and cell growth.110 The first isolation of HMG proteins were in 1982 by 
Lund, from HeLa S3 metaphase and interphase cells.111 The importance of HMG proteins 




during the viral transformation in epithelial thyroid cells. The two-dimensional 
electrophoresis results of the transformed cells reported an increase in the 
phosphorylation of histones H1, H2A, and ubiquitinated H2A.112 Those phosphorylated 
proteins were identified later as HMGA2, HMGA1a, and HMGA1b.112 The 
overexpression of high mobility proteins in the transformed cells was the hint that 
showed the correlation between overexpression HMG proteins and malignant phenotype 
in cells.   
HMGA family was the first group identified and isolated. HMGA is a family 
consisting of four proteins HMGA1a, HMGA1b, HMGA1c and HMGA2. HMGA 
proteins are produced by alternative splicing of the same gene to generate the four 
proteins. HMGA gene contains 3 basic repeat domains in the amino terminal known AT 
hooks. The AT domain can bind with DNA binding domain AT-rich minor groove 
domain in order to contribute to transcriptional activity of many genes.  
HMGB family, however, contains only three members HMGB1, HMGB2, and 
HMGB3. Each protein in this family has two motifs known as box1 and 2, and the C-
terminal. The HMGB box 1 and 2 enhance the interaction of proteins with DNA inside 
the nucleus. HMGB proteins have been reported to loosely bind to chromatin, unlike the 
other high mobility group proteins.113 HMGB1 overexpression has been associated with 
hallmarks of cancer, including increasing angiogenesis, inhibiting apoptosis, induce 
invasion and metastasis.114 
HMGN proteins specially bind to nucleosome which leads to epigenetic 




proteins; HMGN 1 to 5, and all these proteins have 4 major domains, 2 domains have the 
nuclear localization signals domain (NSL1/2), a nucleosome binding domain (NBD), and 
chromatin unfolding domain (CHUD) in the C-terminal domain.115 HMGN proteins play 
a role in development and cellular differentiation.116 HMGN1 and 2 are strongly 
expressed during the embryogenesis.117 Recently, it has been reported that high 
expression of HMGN1 and 2 is observed in the stem cells of the hair follicle, while the 
expression of these proteins are down-regulated in the outer root sheath cells and basal 
layer cells.118 In the in vivo studies, the transgenic mice Hmgn-/- have higher incidence of 
malignant tumors with metastases. Furthermore, the mice fibroblasts altered G2-M 
checkpoint due to change in conditions such as UV, stress, and ionization radiation which 
lead to increase the aggressiveness of the tumor.119 
HMGN3 is expressed in the differentiated tissue, and high expression has been 
detected in the eyes and brain.120 Knockout of HMGN3 in mice correlated with reduced 
efficiency of pancreatic beta islet cells and decreased insulin levels in the mice.121 The 
function of HMGN4 protein is still not known.  HMGN5 is a unique subtype of HMGN 
proteins; this protein does not contain the C-terminal domain or the acidic amino acids. 
HMGN5 is highly expressed in trophoblast giant cells, spongiotrophoblast, and 
trophoblast in placenta.116 
 2.10.1 High Mobility Group A (HMGA) Proteins  
 HMGA proteins are highly expressed during embryogenesis, which indicates the 
important role of this protein in development and growth.110 Human HMGA1 gene is 




mRNA and codes for each AT-hook binding domain in the N-terminal, while the 8th 
exon transcribed for the C-terminal tail. HMGA1a and 1b are alternatively spliced to 
form the two different proteins. On the other hand, HMGA2 located in chromosome 
12q13-15 and consist of 5 exons. The first three exons code for the AT hooks regions 
which are responsible for the DNA binding, however the exons 4 and 5 code for the 







Figure 6. General characteristic of HMGA genes and proteins.110 
 
HMGA1 and 2 proteins were first isolated from HeLa S3 cells.111 In order to 
distinguish the functions of different HMGA proteins, knockout mice were generated 
with either HMGA1 or HMGA2. Fedele et al. reported that mice with homozygous and 
heterozygous HMGA1 deletion develop cardiac hypertrophy and myeloid leukemia.122 
Furthermore, the study suggested the reduction of HMGA1 might lead to deregulation of 
T- and B-cells specific cytokines.122 Another study observed the correlation between 
HMGA1 and type2 diabetes. The normal expression of HMGA1 is required for 
regulation of human insulin receptor gene INSR transcription, and the decrease of 




mice.123 On the other hand, HMGA2-null (A2-KO) and heterozygous mice showed a 
pygmy phenotype with decrease in body size of 60% and 25%, respectively, which 
suggests that HMAG2 plays an important role controlling the body size and a dipocyte 
proliferation and differentiation.124 
Overexpression of HMGA 1 and 2 were also studied in different cancers. The 
correlation between HMGA1 and 2 expressions have been studied in pancreatic 
adenocarcinoma. The study included 40 PanIN (pancreatic cancer) and 40 normal tissues 
which were used as control. The results suggested that HMGA 1 and 2 have a role in 
increasing the progression and malignancy of the pancreatic adenocarcinoma.125 
Moreover, in retinoblastomas, the immunostaining for the tissues showed around 68% 
positive expression forHMGA1 and 75% for HMGA2 in poorly differentiated and highly 
aggressive retinoblastomas.126 
 2.10.2 HMGA Proteins and Mechanisms of Action  
 HMGA proteins can bind to the DNA directly by assembling with various 
transcription factors to form complexes. These complexes have the ability to regulate 
gene expression. For example, HMGA1and NF-κB bind to interferon-β (IFN-β) promoter 
to increase their activity.127 HMGA proteins can improve the affinity of the transcription 
factors to bind to the DNA. For example, HMGA1 enhances the direct binding with 
serum-serum response factor (SRF) in order regulate the cell growth.128 
The immunostaining of specific localization of HMGA proteins in the 
chromosomes during metaphase indicates the important role of this protein in regulating 




(chemicals that have the same binding activity with the AT-DNA groove) to compete 
with HMGA in binding to DNA. Treatment with the drugs shows a complete prevention 
of the condensation of the chromosomes in the metaphase in vivo.129 HMGA proteins can 
modulate the expression of target genes by altering the chromatin structure at 
thepromoter region which leads either to enhancement or suppression of gene 
expression.130 HMGA proteins band to the DNA with high affinity, however, studies 
showed that both HMGA1 and HMGA2 competes with histone H1 for binding to the 
DNA linker. As consequence of that the chromatin will decompact and change the target 
gene expression.131 
 2.10.3 High Mobility Group A2 (HMGA2)  
 HMGA2 acts exclusively as an architecture transcription factor protein.132 It is 
able to alter the chromatin structure by interacting with the transcription machinery 
HMGA2 gene can undergo chromosomal rearrangements in the region 12 q13-15, where 
the gene is located, and due to that rearrangement, HMGA2 gene will disassociate from 
the third intron. As result of that HMGA2 protein will overexpress the truncated form 
(HMGA2 with three AT hook regions in the N-terminal with part of the C-terminus and 
3’untranslated region missing), or most commonly, generation of a fusion between the 
first three exons and other genes.133 Translocation of HMGA2 has been detected in many 
benign tumors of mesenchymal origin such as lipomas where HMGA2 is fused to the 
LIM domain infrom the lipoma (LPP) gene.134-135 The fusion HMGA2 with LIM domain 
causes malignant transformation in NIH3T3 cells.136 Uterine leiomyomata is another 




24).137 FISH mapping and cytogenetic analysis showed the fusion transcripts joined in the 
5’ region of HMGA2 with the 3’UTR region of RAD51L1, which suggested the 
breakpoints in third exon of HMGA2, and all the truncated proteins still have the AT–
hook DNA binding domains.137 
The truncated form of HMGA2 forms as a results of translocation breakpoints at 
the third exon. It has been studied by Battista et al. who conducted an in vivo study with 
transgenic mice overexpressing HMGA2 deprived of the acidic C-terminus; this showed 
a giant and obese phenotype.138 Furthermore, the MRI of the transgenic mice showed 
increase of fat deposition along with other accumulation of abnormal tissues within 
perineal and epididymalareas. On the other hand, mice with null- HMGA2 expression 
showed a pigmy with a reduction in the adipose tissue formation.139 Another study 
performed on transgenic mice overexpressing truncated HMGA2 observed increased 
adipose tissue and inflammation indicative of lipomas.124 
The 3’UTR region in HMGA2 gene can be controlled by lethal-7 (let-7) 
miRNA.14,140 Let-7 gene produces13 precursor sequences (let-7a to j), with three 
precursors produced from the mature let-7a and two from let-7f. There are seven 
complementary let-7 binding sites in 3′UTR of HMGA2, and binding of Let-7 to these 
sites suppresses HMGA2 transcription.141 The expression of let-7 is negatively correlated  
with HMGA2during embryogenesis and development.14 Losing the 3′ UTR in HMGA2 is 






 2.10.4 HMGA2 and EMT  
 EMT is a critical step that allowed cancer cells to invade and escape the local 
tumor and initiate the metastasis. Overexpression of HMGA2 promotes EMT in many 
cancers. In response to TGF-β signaling, HMGA2 associated with Smads to bind to Snail 
gene promoter, leading to up-regulation of Snail expression and induction of EMT.15 
Another study showed that overexpression of HMGA2 up-regulates Twist directly by 
binding to its regulatory gene during EMT.143 Overexpression HMGA2 in response to 
TGF-β signaling was also shown to promote EMT by regulating Snail, Twist, Slug, and 
Id2.144 HMGA2 can activate other pathways to activate EMT programming, such as 
Wnt/β-catenin pathway in gastric cancer.145 In the breast cancer model, HMGA2 has been 
shown to downregulate E-cadherin, the hallmark marker of EMT. Overexpression of 
HMGA2 modulated the chromatin to bind with DNA methyltransferase 3A (DNMT3A), 
which assisted their binding to E-cadherin promoter; that effect could be antagonized by 
treating with a demethylation agent.146 Clinically, HMGA2 is a promising therapeutic 
target in gastric cancer; HMGA2 was highly expressed in gastric cancer tissue compared 
to normal, while knockdown of HMGA2 using shRNA in gastric cancer cell line MKN28 
upregulated E-cadherin (epithelial marker) and downregulated N-cadherin (mesenchymal 
marker), as well as cell migration and invasion. 
 
2.11 Reactive Oxygen Species (ROS) 
 Reactive Oxygen Species (ROS) are free radicals molecules in all aerobic 
organisms. Electrons in atoms carry a maximum of two electrons in their outer shell. 




with parallel spins. ROS have one or more unpaired electron in their outer shell, which 
makes them unstable and ready to undergo any reaction.  In most mammalian cells, 90% 
of the ROS molecules are produced from mitochondria. The reason for that is that 1 to 3 
% of the oxygen consumed in mitochondria is not completely reduced, and as a result, 
ROS molecules are produced.148 The pioneer observation of ROS from mitochondria was 
in early 1966 by Jensen, when he reported the respiratory chain.149 The remaining ROS 
are generated from the electron transfer membrane by NOX/Duox enzymes in different 
tissues. Nox enzymes can be activated during the stressful conditions, such as physical 
damage, starvations, or pathogen attack which make them involve in many biological 
signaling and immune response.150-17 
 During chemical oxidation in non-radical molecules, oxygen reacts with other 
molecules to support the reaction with pairs of electrons present in the opposite spins.151 
However, ROS molecules are generated by transfer of electron leading to formation of a 
sequential reduction tosuperoxide (O2-), hydrogenperoxide (𝐻2𝑂2), andhydroxyl 
reaction152 (see Figure 7) . 
In normal conditions, mitochondria generate ROS in low concentrations which 
are required for cellular signaling. Recent studies have shown the critical role of ROS in  
intercellular signaling ,154 cell proliferation, 155 senescence, 156 differentiation, 157 and 
apoptosis.158 However, excessive quantities of ROS lead to “oxidative stress.” The 
oxidative stress is define as imbalance between the productions and the detoxifications of 
















Figure 7. Generation of ROS and detoxification.153 
 
The accumulation of ROS in the cells is reduced in the mitochondrial before it 
causes stress. Cells have enzymes which respond immediately against production of 
mitochondrial free radicals; but the risk still remains high for the oxidative stress. For 
example, two free radicals, hydrogen peroxide and superoxide, can interact together 
forming new free reactive ions, “hydroxyl radicals,” which can cause cellular damage. 
Usually cells try to avoid formation of the hydroxyl radicals, using scavengers of ROS.155 
These include many enzymes such as superoxide dismutase (SOD), superoxide 
reductases, catalase, glutathione peroxidases (GPX), and ascorbate peroxidises (APX), or 
with non-enzymatic mechanisms which include redox buffers, ascorbate and glutathione 




the 𝐻2𝑂2 and under some conditions can be converting into hydroxyl radicals, while in 
other cases, catalase enzyme converts 𝐻2𝑂2 to water (see Figure 7). 
 2.11.1 ROS and Cancer   
 In cancer cells, ROS levels tend to increase due to high metabolic activity, 
mitochondrial dysfunction and cell signalling deregulation.160 The high concentration of 
ROS may reduce cell dependence on growth factors and  provide a good environment for 
tumor progression.161 The ROS produced can be either extrinsic or intrinsic. Extrinsic 
factors that contribute to increased ROS levels include hypoxia, which deregulates the 
complex III of mitochondria electron transport chain.162 The intrinsic oxidative stress 
involves many signalling pathways, which can alter the cytoskeleton structure of the 
epithelial cells, which leads to breakdown of cell-cell interactions. Elevating the levels of 
ROS can also directly induce EMT. We have shown that prostate cancer cells (ARCaP) 
with overexpression of Snail can undergo EMT and displayed high levels of ROS.163   
Recently there are many studies looked at the cross-taking between ROS and TGF-β 
signalling. One study showed that treating HeLa cells with TGF-β lead to increased 
NOX2/5 and ROS generation, which mediated EMT.164 Rhyu et al, reported that 
activation of TGF-β increased dichlorofluorescein-sensitive cellular ROS, which lead to 
phosphorylation of Smad2, p38 MAPK, and EMT.165 Inumaru et al, showed the role of 
the oxidative stress in regulating dissociation of cell-cell junctions; the study further 
showed that treating the retinal pigment epithelium (ARPE-19) with 200μMH2O2for 
indicated time points (1,6,24h) disrupted the actin filaments, with an increase in stress 




TNF-α.166 It was reported an increase in ROS it also associated with increase in 
HMGA2.167 TGF-β can increase generation of ROS as well as HMGA2 thus promoting 
EMT.161 
 2.11.2 Activator Protein-1 and ROS  
 Activator protein-1(AP-1) is a family of transcription factors; AP-1 complex 
includes three jun proteins (c-JUN, JUN-B, and JUN-D) and four fos proteins (c-FOS, 
FOS-B, FRA-1 and FRA-2). These complexes bind to DNA by either hetrodimerization 
(Fos-Jun) or homodimerization (Jun-Jun).21 The high expression of Jun family members 
have been involved in activation of many genes to control cell proliferation,168 
tumorigenesis, 168-169 and metastasis.169 In prostate cancer, Jun-D activation is necessary 
to induce the oxidative stress.170 A study reported that Jun-D has the ability to bind 
directly to SSAT promoter region in the presence of AR, leading to increased ROS 






MATERIALS AND METHODS 
 
 
3.1 Cell Culture and Reagents 
Prostate cancer cells panel RWPE1, DU145, PC3, 22Rv1 and LNCaP cells (see 
Appendix A, Table A1) were from American Type Culture Collection (Manassas, VA). 
C4-2,ARCaP-E, an epithelial cell line and ARCaP-M the mesenchymal cell line were a 
kind gift from Dr. Leland Chung, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 
The human breast cancer cells lines, MCF-7 and MDA-MB-231 (see Appendix A, Table 
A2), were obtained from ATCC, (Manassas, VA). All these cells were grown in RPMI-
1640 (from Lonza, Alpharetta, GA), supplemented with 10% (v/v) FBS (from Atlanta 
Biological, Flowery Branch, GA); 50 μg/ml penicillin and 100 μg/ml streptomycin, 
except for RWPE1 cells, were grown in Keratinocyte-SFM mediasupplemented with 
keratinocyte supplements (ThermoFisher Scientific ,Grand Island, NY). The African-
American prostate cancer cell line E006AA parental and its more aggressive subline 
E006AA-hT were a kind gift from Dr. Shahriar Koochekpour of Roswell Park Cancer 
Institute (Buffalo, NY). These cells were grown in DMEM from Lonza, Alpharetta, GA, 
with 10% (v/v) FBS, 1X penicillin-streptomycin (Mediatech, Herndon, VA). All cells 
were maintained at37oC with 5% CO2 in a humidified incubator. Nitrocellulose 





rabbit Twist, anti-rabbit ERK1/2, anti-Jun-D antibody, and G3BP1 antibody were from 
Santa Cruz Biotechnology (Santa Cruz, CA). Anti-rat monoclonal Snail antibody and 
anti-rabbit p44/42 MAPK (Erk1/2) were from Cell Signaling Technology, Danvers, MA. 
Goat monoclonal anti-HMGA2, and goat monoclonal anti-vimentin antibody were 
purchased from R&D Systems (Minneapolis, MN). Anti-mouse monoclonal E-cadherin 
was from B.D Bioscinces. Anti-mouse Occludin was from life technologies. Luminata 
and the protease inhibitor cocktail was from Roche Molecular Biochemicals, 
Indianapolis, IN. Rat tail collagen I was from BD Biosciences (Franklin Lakes, 
NJ);UO126 (MEK1/2 inhibitor) was purchased from EMD Callbiochem (Billerica, MA). 
 
3.2 Stable Overexpression of HMGA2 
 LNCaP parental cells were plated in 6 well culture dishes at 80% confluence 
without antibiotics overnight. Next day, cells were transfected with either HMGA2 wild-
type plasmid, HMGA2 truncated pasmid, or empty vector pcDNA 3.1 Neo (provided 
from Addgene, Cambridge, MA) using Lipofectamine 2000 (Invitrogen, San Diego, CA) 
for 72 h. Stable transfectants were selected using 800μg/ml G418 and maintained in 
400μg/ml G418 followed by selection of single colonies; HMGA2 wild-type 
(WT4,WT9,WT21), HMGA2 truncated (TR2,TR18, TR23), and empty vector Neo 
(Neo8, Neo19). Selected clones were tested for HMGA2 expression by western blot 
analysis.  
 
3.3 Western Blot Analysis  
 Cells were lysed in a modified RIPA buffer as described previously.172  





µg of cell lysate was resolved using 10% sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis, followed by trans-blotting onto nitrocellulose membrane. Membranes 
were incubated with appropriate primary and secondary antibody, followed by 
visualization using Luminata Forte ECL reagent. The membranes were stripped using 
Restore western blot stripping buffer (Pierce Biotechnology, Rockford, IL) prior to 
reprobing with a different antibody.  
 
3.4 Treatments with MAPK Inhibitor (U0126) 
 Cells (2×106) were plated in T-75 flask overnight; the next day, cells were serum 
starved for 2h followed by treatment with 20μM U0126 or 0.005%DMSO for 72h, prior 
to collecting cell lysate or performing cell migration/proliferation assays. 
 
3.5 Immunofluorescence 
Cells (5×103) were plated into 16 well chamber slides (Bio-Tek, Nunc, Winooski, 
VT), the cells were fixed with methanol/ethanol 1 1 volume and blocked with 5% goat 
serum. Subsequently, slides were incubated with primary antibody at 1:50 or 1:100 
dilutions in Dako antibody diluents solution for 1h at room temp, washed with 1× TBS-T 
(Dako, Camarillo, CA), then incubated with secondary antibody in the dark for 1h at 
room temp. Secondary antibodies used were goat anti-rabbit Oregon green 488, anti-
mouse Alexa red 594, and rabbit anti-Goat IgG Alexa Fluor 594 (Invitrogen, Carlsbad,  
CA). Slides were washed prior to counterstaining with DAPI (1 µg/ml, Santa Cruz 
Biotechnology, Santa Cruz, CA). Slides were mounted using Fluoro gel mounting 
medium (Electron Microscopy Sciences, Hatfield, PA). Fluorescence microscopy was 






 We examined the expression of HMGA2 in normal human prostate tissue and 
different stages of prostate cancer by immunohistochemistry (IHC) utilizing tissue 
microarrary (US Biomax;PR8011a). IHC was performed using the Avidin-biotin method. 
Tissue was deparaffinised in xylene and rehydrated using alcohol. Endogenous 
peroxidase activity was blocked with 3% hydrogen peroxide, followed by 10% serum to 
avoid non-specific binding. Sections were incubated with a 1:200 primary antibody 
against HMGA2 at 4°C overnight followed by a biotinylated secondary antibody, and 
incubation with avidin-biotin complex (Vector, Burlingame, CA). Immunoreactivity was 
visualized using diaminobenzidine (Sigma-Aldrich, St. Louis, MO, USA). The slide was 
subsequently counterstained with hematoxylin and mounted with xylene solution.  
Images were acquired using the Leica Aperio VERSA. 
 
3.7 Cell Migration  
 We utilized Costar 24-well plates containing a polycarbonate filter insert with an 
8-µm pore size, to coat with 4.46 µg/ µl rat tail collagen I (BD Bioscience, Bedford, 
Bovine Serum (DCC), whereas the lower chamber contained RPMI supplemented with 
10% FBS. After 48h, cells that migrated to the bottom of the insert were fixed, stained 
with 0.05% crystal violet, and counted to obtain the relative cell migration. Each 
experiment was done in triplicate, and the graphs represent an average of the 3 wells. The 






3.8 Cell Viability Assay 
 LNCaP Neo, LNCaP HMGA2 WT, and HMGA2 TR, or LNCaP HMGA2 WT 
and TR HMGA2/Jun-D siRNA cells were plated at a density of 2,000 cells per well in 
96-well plates and allowed to attach overnight. Viability was assessed daily using the 
CellTiter 96® Aqueous One Solution Cell Proliferation Assay according to the supplier's 
protocol.  
 
3.9 Real Time (RT)-PCR 
Total RNA was isolated by using an RNeasy Mini Kit (Qiagen, Valencia, CA) 
Gene expression was defined as the threshold cycle number (CT). Mean fold change in 
expression of the target genes were calculated using the comparative CTmethod (RU; 2
-
ΔCt). All data were normalized to the quantity of RNA input by Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH). The following primers were used the following 
primers HMGA2 WT Forward 5’- GATCCACTGCTGCTGAGGT-3’; Revere 5’- 




3.10 ROS Assay  
 Cells were cultured to approximately 80% confluency, trypsinized, counted and 
re-suspended in 20 µM of CM-DCFDA and incubated at 37°C for 1h. The reaction was 
stopped on ice and the cells were centrifuged. 1x104 cells resuspended in PBS were 
plated in a black walled 96-well plate and read immediately at 485nm excitation and 





3.11 Proteomic Profiling of LNCaP Cells with WT/TR HMGA2 Overexpression 
 3.11.1 Subcellular Fractionation for HMGA2 WT  
 Subcellular fractionations were performed for LNCaP cells overexpressing 
HMGA2 WT per the manufacturer's instructions (Thermo Scientific). Briefly, cells at 80–
90% confluence were lysed in a series of buffers containing protease inhibitors (25X) 
with CERI (100 µl), CERII (5.5 µl), or NER (50 µl). Centrifugation steps were performed 
to obtain a non-nuclear fraction and an intact nuclear pellet, followed by further lysing to 
isolate the nuclear fraction.  
 3.11.2 Cell Lysis, Reduction, Alkylation, and Trypsin Digestion  
 Both control, LNCaP Neo (empty vector), and case, LNCaP HMGA2 WT 
(nuclear extract) or TR (cytoplasmic cell extract)cell pellets were extracted with RIPA 
buffer (1.5 M Tris pH 8.8, 1.75 g NaCl, 2 mL sodium dodecyl sulfate 10%, 2 mL Triton 
X-100; all reagents from Thermo Fisher Scientific, Waltham, MA). The cells were 
incubated on ice for 30 min, followed by 5 min sonication and centrifugation at 20,000 
rpm for 5 min to remove insoluble material from the crude lysate. The cell lysis of both 
control and HMGA2 WT/TR were performed in triplicate with 5 µg of total proteins. 
Each replicate sample was added into 100 µl of 200 mM TEAB (Sigma-Aldrich, St. 
Louis, MO). Reduction was performed by adding 5 µl of 200 mMTris (2-carboxyethyl) 
phosphine TCEP (Sigma-Aldrich, St. Louis, MO) and incubating for 1h at 55°C. Then, 
alkylation was carried out by adding 5 µl of 375 Mm iodoacetamideand (Bio-Rad 
Laboratories, Hercules, CA) incubating for 30 min without light at room temperature. 





acetone- precipitated protein pellets were suspended with 100 µl of 200 mM TEAB and 
2.5 µg of sequencing grade modified trypsin (Promega Corp., Madison, WI) was applied 
to digest each replicate overnight at 37°C. 
 3.11.3 TMT Isobaric Labelling, Fractionation, and Desalination  
 According to the manufacturer’s protocol, tandem mass tags TMT (Thermo 
Scientific) with different molecular weights (126~131 Da) (Thermo Scientific, Waltham, 
MA) were applied as isobaric tags for quantification analysis. Three control samples were 
labeled with TMT126 (batch 1), 127 (batch 2), and 128(batch 3), and three case samples 
with TMT-129(batch 1), 130(batch 2), 131(batch 3). All of six TMT-labelled samples 
were finally combined together with equal ratios. The combined TMT labelled peptide 
mixture was fractionated with a strong cation exchange SCX column (Thermo Fisher 
Scientific, Waltham, MA) on a Shimadzu Ultra Fast Liquid Chromatography UFLC 
equipped with an ultraviolet detector (Shimadzu, Columbia, MD). Total 14 fractions were 
collected based on SCX chromatogram peaks, followed by desalination with a C18 solid-
phase extraction (SPE) column (Hyper-Sep SPE Columns, Thermo Scientific). 
 3.11.4 LC-MS/MS Analysis, Database Search, and TMT Quantification 
 Peptides were analyzed on a LTQ-Orbitrap XL (Thermo Scientific) interfaced 
with an Ultimate 3000 Dionex LC system (Dionex, Sunnyvale, CA) by using high mass 
resolution to identify peptides and high energy collision dissociation (HCD) to quantify 
reporter ions. The reverse-phase HPLC system consisted of a peptide Cap-Trap cartridge 
(0.5 by 2 mm) (Michrom Bio Resources, Auburn, CA) and a prepacked BioBasic C18 





Woburn, MA) fitted with a FortisTip emitter tip. The Orbitrap mass spectrometer was 
operated in a data-dependent mode in which each full MS scan (60,000 resolving power) 
was followed by six MS/MS scans where the three most abundant molecular ions were 
dynamically selected and fragmented by collision-induced dissociation with a normalized 
collision energy of 35%, and the same three molecular ions were also scanned by HCD-
MS2 with collision energy of 45%. MS scans were acquired in profile mode and MS/MS 
scans in centroid mode, respectively. The protein search engine Sequest (Thermo 
Scientific) was used for peptide matching and protein identification. The minimum 
number of peptides used for identification and quantification of proteins was one unique 
peptide. For TMT quantification, the ratios of TMT reporter ion intensities in MS/MS 
spectra (up to six reporter ions ranging from m/z 126.12 to m/z 131.14) from raw data 
sets were used to calculate fold changes of proteins between control and HMGA2 
WT/TR. 
 
3.12 Immunoprecipitation  
 Cells (2x106) were plated overnight, whole cell lysates for HMAG2 WT/TR were 
centrifuged at 15,000 for 30 minutes at 4°C, and then 5μg of protein from each sample 
was incubated with HMGA2 antibody overnight at 4°C on a rocking platform. Protein 
A/G PLUS Agarose Beads (1:10, Santa Cruz Biotechnology) were added to each sample 
for 2 hours at 4°C with gentle agitation. Cell lysates were washed 2X in 1X PBS (max 
speed for 5 min at 4°C), boiled in Laemellisample buffer for 5 minutes, followed by 10% 
SDS-PAGE. Protein was transferred to a membrane, blocked in 5% milk/TBST, 





Biotechnology).Primary antibodies were detected with corresponding with peroxidase 
conjugated anti-mouse secondary antibodies (1:4000; Minneapolis, MN) and enhanced 
chemiluminescence (Luminata; Fisher Scientific). 
 
3.13 Treatment with Camalexin 
ARCaPM 1x106 cells were plated in p-100 petri-dish plates overnight. The cells 
treated cells with 10, 50, and 100μMcamalexinfor 72h; we then preformed ROS assay, as 
described previous, and protein lystes were collected to detect HMGA2 expression. 
 
3.14 Statistical Analysis 
Data were analyzed by a paired student's t-test or ANOVA using GraphPad Prism 
software. For all experiments * means 0.05 >p value > 0.01, ** means 0.01 >p value > 











4.1 HMGA2 Expression Increases with Prostate Cancer Progression 
Initially, we wanted to evaluate the basal expression of the HMGA2 protein in 
human prostate cell lines and patient tissue. Western blot analysis showed highest MGA2 
expression in PC3, ARCaP-E, and ARCaP-M aggressive prostate cancer cells (see Figure 
8A).  Interestingly,PC3 cells showed two bands that might be due to the truncated 
isoform or post-translation modification as has been observed for HMGA1 protein in PC3 
cell lines.173 Immunofluorescence analysis illustrated that PC3 and ARCaP-M 
(mesenchymal phenotype) showed both cytoplasmic and nuclear localization of HMGA2, 
however, ARCaP-E (epithelial phenotype) showed predominantly cytoplasmic expression 
of HMAG2 (see Figure 8B).  
We utilized a prostate tissue microarray to analyze the expression by IHC 
staining. This revealed expression of HMGA2 was detectable with very low expression in 
normal tissue that was mainly localized within the cell membrane. The HMGA2 levels 
and the translocalizationfrom cytoplasmic toward nuclear expression were increased with 
the stage of prostate cancer as well as bone metastasis sample (see Figure 9). Therefore, 
































































































Figure 8. HMGA2 expression in prostate cancer cell lines. (A) Western Blot analysis 
was used to detect the protein expression of HMGA2 in prostate cancer cell lines.B-actin 
was utilized as a loading control. (B) Immunofluorescence illustrates nuclear/cytoplasmic 
localization of HMGA2 in PC3 and ARCaP-M (Mesenchymal phenotype), and 































Figure 9. HMGA2 increases with prostate cancer progression. Immunohistochemical 
(IHC) staining of prostate cancer adenocarcinoma tissue microarray sections was 
performed. Representative images of HMGA2 in various stages of prostate cancer show 
that HMGA2 localization becomes more nuclear with tumor progression (magnification 
20X, Inset 40X). 
 
Immunofluorescence analysis illustrated that PC3 and ARCaP-M (mesenchymal 
phenotype) showed both cytoplasmic and nuclear localization of HMGA2; however, 
ARCaP-E (epithelial phenotype) showed predominantly cytoplasmic expression of 
HMAG2 (see Figure 9).  
 
4.2 Overexpression of Truncated vs Wild-type HMGA2 in Prostate Cancer Cell 
Lines 
 
 To test the differential role of HMAG2 isoforms in prostate cancer cells, we 




vector) cDNA into LNCaP cells, which has low endogenous levels of HMGA2. 
Immunofluoresence revealed that WT HMGA2 displayed nuclear and cytoplasmic 
localization while TR HMGA2 was exclusively cytoplasmic (see Figure 10A). The stable 
overexpression of HMGA2 shows change in morphology in the both isoforms compared 












Figure 10. Overexpression of HMGA2 WT vs TR in prostate cancer cell lines. Stable 
transfection of HMGA2 WT, TR, or Neo (empty vector) in LNCaP prostate cancer cells. 
(A) Immunofluorecence analysis of WT vs TR HMGA2 in LNCaP cells showed nucleus  
localization for the WT HMGA2, while TR HMGA2 has cytoplasmic localization.  
(B) LNCaP cells transfected with HMGA2 WT or TR shows difference morphology.  
 
4.3  Overexpression of WT HMGA2 Induces EMT Prostate Cancer, while Both WT 
and TR HMGA2 Increase Cell Viability and Migration 
 
 The exogenous WT HMGA2 protein in LNCaP cells was at the same molecular 
weight as the endogenous expression of HMGA2 in ARCaP and PC3 (upper band) 
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detected at16KDa (see Figure 11A), which corresponds to loss of part of the C-terminus 














Figure 11. Overexpression of HMGA2 WT induces EMT and cell migration, while 
HMGA2 TR increases cell migration and viability. (A) LNCaP cells were stably 
transfected with wild-type (WT), truncated (TR) HMGA2 or Neo (empty vector). EMT 
markers tested by western blot analysis included mesenchymal markers (Snail, Twist, and 
vimentin) and epithelial markers (E-cadherin and Occludin).Actin was utilized as a 
loading control. (B) immunofluorescence was performed with antibodies to HMGA2, 
Snail, vimentin and E-cadherin. It showed that expression of HMGA2 WT is 
nuclear/cytoplasmic while HMGA2 TR is predominantly cytoplasmic. HMGA2 WT 
displayed high expression of Snail, vimentin, and cytoplasmic E-cadherin compared with 
empty vector Neo, therefore HMGA2 WT promotes EMT. (C) Cell migration across 
transwells coated with collagen in boyden chamber or (D) Cell viability using MTS 
assaywas performed with LNCaP cells overexpressingHMGA2 WT, TR or Neo control. 
Results are representative of 3 independent experiments. (n = 3, ****p< 0.0001, ***p< 
0.001, **p < 0.01). Values were normalized to LNCaP Neo and the mean± SEM of data 
were obtained from three independent replicate experiments. Statistical analysis was done 








 We examined the expression of EMT markers by western blot analysis. 
Overexpression of HMGA2 WT but not TR increased the expression of mesenchymal 
markers, Snail, vimentin, Twist, compared to LNCaP Neo (see Figure 11A). From 
several colony selections, we chose three representative colonies for WT (HMGA2 WT4, 
WT9, WT21) and TR (HMGA2 TR2, TR18, and TR23), and two representative controls 
(Neo8, Neo19). Immunofluorescence analysis confirmed western blot results and further 
showed that although western blot showed that epithelial markers E-cadherin and 
Occludin did not decrease but in fact seemed higher for both WT and TR overexpression 
(see Figure 11A), the localization was no longer at the membrane as seen for LNCaP 
Neo, but cytoplasmic for WT and nuclear for TR (see Figure 11B). Functionally, we 
detected a significant increase in cell viability with cells overexpressing HMGA2 TR 
compared with LNCaP Neo control, while no significant change in cell viability was 
observed with cells overexpressing HMGA2 WT (see Figure11C). However, LNCaP 
cells overexpressing HMGA2 WT and TR both significantly increased the cells’ 
migratory potential across collagen compared to the LNCaP Neo control, with 
HMGA2WT having a higher effect (see Figure 11D). Therefore, HMGA2 WT promotes 
cell migration and EMT while HMGA2 promotes cell viability and cell migration but not 
EMT. 
 
4.4 HMGA2 WT Induces EMT via ERK Pathway 
 HMGA2 and Smads bind to Snail promoter to increase the expression of Snail 
followed by EMT transition.175 Previously we have been demonstrated that Snail can 




 We sought to examine whether HMGA2 WT can regulate EMT via the ERK 
pathway. We showed by western blot analysis, an increase in phospho-ERK (p-ERK) 
expression after we overexpressed both WT and TR HMAG2, as compared to LNCaP 
Neo (see Figure12A).Western blot analysis showed that treatment with MAPK inhibitor, 
U0126, effectively inhibited p-ERK in cells overexpressing HMGA2 WT and TR (see 
Figure 12B). Interestingly, we detected a decrease in the mesenchymal markers, Snail 
and vimentin, and an increase in E-cadherinin HMGA2 WT cells treated with U0126, 
compared to untreated cells or cells treated with DMSO control, while HMGA2 TR cells 
were unaffected (see Figure 12B). Treatment with UO126 decreased cell migration in 
LNCaP cells overexpressing HMGA2 WT compared with control DMSO (p=0.267), but 
functionally had no effect on cell viability (see Figure 12C) or migration for cells 
overexpressing HMGA2 TR (see Figure 12D). Therefore, wild-type HMGA2 induces 
EMT in part via the MAPK signaling pathway. 
 
4.5 Expression of Truncated vs Wild-type HMGA2 in Prostate Cancer Cell Lines  
We have previously explored the expression of HMGA2 protein in prostate cell 
lines. We confirmed by western blot that expression was low in RWPE1 normal 
transformed prostate epithelial cells, but aggressive ARCaP-E/M and MDA-PCa-2a/2b 
prostate cancer cells expressed the highest levels of wild-type HMGA2 (approx. 23 kDa), 
although interestingly, the HMGA2 protein in MDA-PCa-2a/2b was a slightly higher 
molecular weight (approx. 25 kDa) possibly due to post-translational modifications (see 



































Figure 12. HMGA2 inducing EMT via ERK pathway. (A)LNCaP cells overexpressing 
HMGA2 WT or TR were utilized to analyze phospho-ERK (p-ERK) expression by 
western blot and compared to LNCaP Neo. Total-ERK levels were also analyzed and 
actin was utilized as a loading control. B) LNCaP cells overexpressing HMGA2 WT or 
TR were treated with 20 µMU0126 (MAPK inhibitor) or 0.005% DMSO control for 72 h 
followed by analysis of (B) EMT markers by western blot analysis. (C)  Relative cell 
migration across transwells coated with collagen after 48 h showed a decrease in cell 
migration of cells overexpressing HMGA2 WT compared to DMSO control (WT 
HMGA2 DMSO) with no significant change in migration with cells overexpressing 
HMGA2TR.  (D) Cell viability (MTS) assay performed for up to 3 days with LNCaP 
cells overexpressing HMGA2 WT and TR HMGA2 showed no significant changes after 
















Figure 13. Expression of truncated vs wild-type HMGA2 in prostate cancer cell lines. 
(A)Western Blot analysis was used to detect the protein expression of HMGA2 in 
prostate cancer cell lines.Tubulin was utilized as a loading control. (B) RT-PCR show the 
expression of wild-typeHMGA2 mRNAis high in PC3 and ARCaP-M aggressive prostate 
cancer cells as compared to normal RWPE1. (C) TruncatedHMGA2 expression is high in 
ARCaP-M and E006AA-hT.Statistical analysis was done with GraphPad Prism; (****p< 
0.0001, ***p< 0.001, **p < 0.01, * p< 0.05). 
 
The lower molecular weight truncated HMGA2 (approx. 17 kDa) was relatively 
high in RWPE1, DU145, PC3 prostate cells and MDA-MB-231 breast cancer cells, 
moderate in ARCaP-E/M, E006AA-hT, and low in LNCaP, 22Rv1, C4-2, E006AA, 
MDA-PCa-2a/b, and MCF-7 breast cancer cells (see Figure 13A).We utilized primers 
designed to recognize mRNA expression of HMAG2 wild-type or truncated as previously 
published, and performed RT-PCR, normalizing the relative expression of HMGA2 either 
wild-type or  truncated to RWPE1 the normal prostate cells. The RT-PCR shows a high 







Figure 13B). On the other hand, truncated HMGA2 was detected in PC3, ARCaP-M, and 
E0066A-hTprostate cancer cell lines (see Figure 13C).   
 We also confirmed that these primers work in LNCaP cells overexpressing either 
wild-type or truncated HMGA2 that we previously generated. Therefore, prostate cancer 
cell lines have varying levels of wild-type and truncated HMGA2. 
 
4.6   Overexpression of TR HMGA2 Activates Jun-D in LNCaP Prostate Cancer   
Cells and Induces Cell Migration via ROS 
 
First we analyzed the expression of Jun-D in the LNCaP overexpressed HMGA2 
WT, TR, or Neo empty factor. The results showed that both wild-type and more so 
truncated HMGA2 increases the expression of Jun-D compared to Neo (see Figure14A). 
Immunostaining of these cells revealed that both wild-type and truncated 
HMGA2promoted nuclear localization of Jun-D (see Figure 14B). Of note, as we have 
previously shown, wild-type HMGA2 is nuclear while truncated HMGA2 displays 
cytoplasmic localization (see Figure 14B). Since ROS has been shown to be downstream 
of Jun-D,176 we analyzed the ROS generation in these cells. We found a significant 
increase in ROS generation in LNCaP cells overexpressing truncated HMGA2, but 
surprisingly not with cells overexpressing wild-type HMGA2 (see Figure 14C). Thus, 
although both wild-type and truncated HMGA2 both promote nuclear localization of Jun-























Figure 14. Overexpression TR HMGA2 activate Jun-D in LNCaP prostate cancer cells 
and induce cell migration via ROS. Different clones selected after stable transfected with 
cDNA HMGA2 WT and TR. (A) Western blot utilized to detect the expression of Jun-D 
in HMGA2 overexpressed cells show an induce Jun-D expression and (B) 
Immunofluresence show Jun-D is translocated into nucleus. (C) WT HMGA2 increases 
the cells migration, but TR HMGA2 induces ROS generation.   
 
 
4.7  Knockdown of Jun-D in HMGA2 Overexpressed Cells Decreases Migration and  
ROS. 
 
Since Jun-D was regulated by HMGA2, we examined the effect of transient 
knockdown using Jun-D siRNA in LNCaP cells overexpressing wild-type or truncated 
HMGA2, and compared it to control siRNA. We confirmed knock down of Jun-D by 
western blot analysis (see Figure 15A). We observed a slight but significant decrease in 
the generation of ROS following Jun-D knockdown in cells with truncated HMGA2 (see 



























Figure 15. Knockdown Jun-D in TR HMGA2 overexpressed cells decreases ROS and 
migration. (A)Jun-D knockdown using siRNA; (A) decreases Jun-D expression and (B-




Surprisingly, knockdown of Jun-D actually increased ROS in LNCaP cells 
overexpressing wild-type HMGA2 (see Figure 15B). We performed a migration assay 
following Jun-D knockdown which showed a decrease in the ability of the cells to 
migrate in cells with truncated HMGA2, while conversely, increased cell migration in 
cells with wild-type HMGA2 (see Figure 15C). However, cell viability was not affected 
by Jun-D knockdown for either cell line (see Figure 15D). Therefore, Jun-D activation by 
truncated HMGA2 appears to be important for ROS induction and cell migration, while it 








4.8 Truncated HMGA2 Interacts with Oxidative Stress Protein, G3BP1 
In order to explore further the differing roles of wild-type vs truncated HMGA2, 
we employed a proteomics approach. Since wild-type HMGA2 is mainly nuclear, we 
isolated nuclear extract from LNCaP cells overexpressing wild-type HMGA2 and utilized 
this to immunoprecipitate with HMGA2 antibody. Since truncated HMGA2 is 
cytoplasmic, we utilized whole cell extract from LNCaP cells overexpressing truncated 
HMGA2 to immunoprecipitate with HMGA2 antibody. Proteomic analysis was 
subsequently performed to examine all HMGA2-interacting proteins. The Venn diagram 
shown represents some of the proteins that bind to either wild-type or truncated HMGA2 











Figure 16. Truncated HMGA2 interacts with oxidative stress protein, G3BP1. (A) Venn’ 
diagram represent different genes expressed with WT and TR HMGA2. (B) 
Immunoprecipitation conform a physical interacts TR HMGA2 only with G3BP1 to 
promote oxidative stress. (C) Immunohistochemical analysis was performed using 
microarray prostate adenocarcinoma tissue.HMGA2 show chronic inflammation prostate 

























































Proteomic analysis revealed proteins that bound to wild-type HMGA2 and proteins 
that bound to truncated HMGA2 (see Appendix B, Table B1 and Table B2). There were 
much fewer proteins found to bind to wild-type HMGA2 probably because nuclear lysate 
was used, whereas cell lysate was used for truncated HMGA2-binding proteins, and since 
truncated is localized within the cytoplasm, it should have pulled down cytoplasmic 
interacting proteins. We took one of the proteins (G3BP1) shown to interact with 
truncated HMGA2 for verification using co-immunoprecipitation. G3BP1 is a 
cytoplasmic stress granules protein that responds to oxidative stress.177  We utilized 
nuclear cell lysate from LNCaP cells overexpressing wild-type or cytoplasmic fraction 
from truncated HMGA2 and performed an immunoprecipitation (IP) with HMGA2 
antibody followed by western blot with G3BP1 antibody. The results showed the 
interaction between truncated HMGA2 and G3BP1, but not with wild-type HMGA2 (see 
Figure 16B). This suggests that truncated HMGA2 interaction with G3BP1 may be 
associated with oxidative stress in prostate cancer. Since hyperplasia chronic 
inflammation is associated with oxidative stress, we stained normal, benign hyperplasia 
and chronic inflammation tissue with HMGA2. Interestingly we found cytoplasmic 
staining for HMGA2 in prostate hyperplasia and chronic inflammation tissue, which 
indicates that HMGA2 is associated with oxidative stress (see Figure16C). 
 
4.9  Camalexin Treatment Induces ROS and Decreases HMGA2 in ARCaPM Cells 
in vitro and in vivo  
 
 Previously in our lab, we were able to show that camalexin treatment decreased 
cell proliferation and increased apoptosis in aggressive prostate cancer cell lines 




we treated ARCaPM with different concentrations of camalexin (25 µM, 50µM, 100µM, 
and 200µM). We found that the expression of HMGA2 significantly decreased with the 
high concentration (200 µM) of camalexin (see Figure 17A).These concentrations also 






















Figure 17. Camalexin inhibits HMGA2 and increases ROS in vitro. ARCaPM cells were 
treated with different concentrations of camalexin and analyzed by (A) western blot and 
(B) ROS levels. 
 
 
In order to investigate the effect of camalexin in vivo, ARCaP-M cells were 
injected subcutaneously into nude mice followed by treatment with different 
concentrations of camalexin for 8 weeks. Tumors volumes were measured weekly. The 
results showed no statistical difference in tumor size with the different camalexin 
HMGA2
B-Actin




treatments (see Figure 18A).  Mice injected with 100 mg/kg camalexin had to be 













Figure 18. Camalexin may decrease tumor volume. ARCaPM cells were injected 
subcutaneously into nude mice and treated with various concentrations of camalexin.  
(A) Mice were sacrificed after 8 weeks and tumor volume was plotted. (B) Mice treated 
with camalexin (high dose of 50-100 mg/kg gave side effects. (C) Tumor xenografts were 
isolated, sectioned and stained for HMGA2 by IHC. 
 
Tumor xenografts were stained with HMGA2 antibody by IHC which showed a 
significance decrease in HMGA2 expression with increasing dosage of camalexin. These 
observations suggest that HMGA2can be therapeutically targeted by camalexin to reduce 
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High Mobility Group A2 (HMGA2) expression has been reported in cancers such 
as pancreatic cancer,178 lung cancer,179 and recently in a canine prostate cancer model.25 
Due to chromosomal rearrangements within HMGA2 gene, loss of the 3’UTR regulatory 
region can occur, which leads to overexpression of HMGA2 protein due to deletion of the 
Let-7 miRNA suppressor binding sites.180 Both HMGA2 isoforms, wild-type (WT)181 and 
truncated (TR) have been reported to up-regulated in cancers including uterine 
leiomyoma,182 bone and soft tissue chondromas,183 and lipomas.184 Studies also show that 
HMGA2 promotes EMT 144, 185 and induces metastasis in several cancers.186 However, 
HMGA2 expression in human prostate tissue and the role of HMGA2 isoforms in 
prostate cancer has not been reported. In this study, we sought to investigate the 
differential roles of HMGA2 isoforms in prostate cancer. 
Here, we demonstrate that HMGA2 is highly expressed in the aggressive prostate 
cancer cell lines, PC3, ARCaP-E and ARCaP-M. Furthermore, immunofluorescence 
shows HMGA2 is cytoplasmic in ARCaP-E or nuclear/cytoplasmic localization in 
ARCaPM and PC3 cells. PC3 displayed two bands which might be due to post translation 
modification or truncated protein. In patient tissue, we found an increase in HMGA2 
expression along with translocation into the nucleus with prostate cancer progression the 




carcinoma development.187 In our study, lower grade prostate cancer tissues showed 
cytoplasmic expression of HMGA2 along with positive expression in stroma. Studies 
showed combined expression HMGA2 and AR in the stroma increases the invasiveness 
of prostate cancer.188 We observed nuclear expression of HMGA2 in later grade 3and in 
bone metastatic tissue. When we stably overexpressed HMGA2 truncated or wild-type 
cDNA in LNCaP cells, we noted cytoplasmic localization of HMGA2 truncated isoform, 
while HMGA2 wild-type showed nuclear/cytoplasmic localization. We also showed that 
wild-type HMGA2 but not the truncated HMGA2 was able to induce the EMT by 
increasing expression of mesenchymal markers, Snail, Twist and vimentin. Although 
epithelial marker expression was not decreased, it was no longer at the membrane but 
cytoplasmic for HMGA2 WT and interestingly, nuclear for HMGA2 TR. We have 
previously shown that Snail overexpression in LNCaP cells induced EMT without 
significantly changing E-cadherin expression, but its translocation from the membrane to 
the nucleus.189 Additionally, studies have reported E-cadherin cleavage at  its cytoplasmic 
domain via p120 leads to translocation of E-cadherin into the nucleus and gene 
transcription.190 It is, therefore, possible that truncated HMGA2 may mediate oncogenic 
activity via nuclear E-cadherin by mechanisms that are unknown at this time.  
We found that exogenous overexpression of HMGA2 WT and TR increases the 
levels of phospho-ERK. Furthermore, inhibiting the MAPK signaling pathway using 
U0126 antagonized HMGA2 WT-mediated EMT and cell migration, without affecting 
TR-mediated cell viability or migration. That suggested HMGA2 WT utilizes MAPK 




membrane. This is similar to a study by Li et al. that found HMGA2 translocated from 
signaling pathway to induce EMT transition in prostate cancer.  Our study shows that 
overexpression of HMGA2 TR increases cell proliferation and migration, which was 
unaffected by inhibiting MAPK signaling with U0126 inhibitor. Previous studies have 
shown that overexpression of truncated HMGA2 in transgenic mice increased 
proliferative hematopoiesis along with hypercellular bone marrow and splenomegaly 
with extramedullary erythropoiesis.16 However, others showed that full-length HMGA2 
has the oncogenic activity while its truncated form has no critical role in cellular 
transformation in mesenchymal tumors.181 Therefore, future studies are needed to 
delineate the functional significance of the increase in ERK phosphorylation by HMGA2 
TR for better understanding of the role of TR HMGA2 in cancer.  
Additional study into the expression of truncated HMGA2 vs wild-type HMGA2 
not only of protein but also mRNA were evaluated in prostate cancer cell panels 
comparing normal transformed prostate epithelial cells (RWPE1) to prostate cancer cell 
lines. Truncated HMGA2 mRNA was detected in RWPE1 and some prostate cancer cells 
such as PC3, ARCaP-E/M, and E006AA-hT with very low expression in LNCaP, 22Rv1, 
C4-2, E006AA, MDA-PCa-2a/b. The wild-type was detected in the aggressive prostate 
cancer cell lines (PC3 and ARCaP-E/M).However, expression of wild-type HMGA2 was 
low in RWPE1 normal transformed prostate epithelial cells, with ARCaP-E/M and MDA-
PCa-2a/2b metastatic prostate cancer cells expressing the highest levels of wild-type 




 Interestingly, the HMGA2 protein in MDA-PCa-2a/2b was a slightly higher 
molecular weight compared to ARCaP-E/M possibly due to post-translational 
modifications. Therefore, wild-type HMGA2 appears to be associated with metastatic cell 
lines (except for C4-2), which would follow high nuclear expression of HMGA2 in bone 
metastatic patient tissue. It was more difficult to discern a pattern of expression for 
truncated HMGA2, except to note that it was negligible in androgen receptor expressing 
cells. A study conducted by Zong et al., reported for the first time the cytoplasmic 
expression of HMGA2 in normal skin tissue, while, HMGA2 translocated into the 
nucleus in carcinoma tissue samples.187 We also previously showed that early grade 
prostate cancer tissue expresses predominantly cytoplasmic HMGA2 while higher grade 
and metastatic tissue display more nuclear HMGA2 expression. It will be imperative in 
future to use the truncated vs wild-type HMGA2 primers to distinguish between the wild-
type and truncated HMGA2 expression in prostate cancer patient tissue. 
Jun-D is a member of AP-1 transcription factor complexes. Early work in rat 
thyroid transformed cells reported that Jun-B and fra-1genes are target genes 
transcriptionally activated HMGA2 required for neoplastic transformation.191 In our study 
we have been shown that overexpression of HMGA2 may induce the expression of active 
Jun-D in prostate cancer cells. We showed that overexpression of both wild-type and 
truncated HMGA2 led to translocation of Jun-D from cytoplasm into nucleus. Jun-D is 
well known to induce generation of ROS initiating the oxidative stress cascade.170, 192 We 
were able to see a significant increase in ROS generation associated with increased cell 




Jun-D knockdown. Selvaraj et al., have been reported the role of Jun family (Jun-D, c- 
jun, and B-Jun) in regulating cell migration in prostate cancer cells, where they showed 
that ERK can interact with Jun-D to promote cell migration without affecting cell 
proliferation.193 We similarly observed that Jun-D knockdown did not affect cell 
proliferation in truncated HMGA2-expressing cells. 
Paradoxically, even though wild-type HMGA2 also caused nuclear 
translocalization of Jun-D, knockdown of Jun-D had the opposite effect in causing an 
increase in ROS and cell migration, suggesting that wild-type HMGA2 regulation of Jun-
D is inhibitory. This contrasting effect of wild-type vs truncated HMGA2 on Jun-D may 
be explained by differences in interacting partners which may lead to differing signals. 
As such we sought to determine whether wild-type and truncated HMGA2 have different 
interacting partners by IP followed by proteomics (see Appendix B, Table B1 and Table 
B2). We did find that these isoforms interact with distinct proteins. In fact, truncated but 
not wild-type HMGA2 bound to G3BP1 protein associated with oxidative stress. G3BP1 
is a cytoplasmic RNA binding protein found in stress granules (SGs) that responds to 
oxidative stress.194 It is plausible that in response to increased ROS triggered by HMGA2, 
stress granules are formed which involves G3BP1 interacting either directly or indirectly 
with HMGA2 in an attempt to regulate oxidative stress; this will need to be tested further. 
Interestingly, we also found that IHC staining of hyperplasia and more so chronic 
inflammatory prostatic tissue showed HMGA2 staining within the cytoplasm, suggesting 




Furthermore, another protein interacted with HMGA2 TR from the proteomics 
data is protease serine 3 (PRSS3). Studies have shown that PRSS3 is up-regulated in 
metastatic pancreatic cancer195 and malignant prostate cancer.196 Cytokeratin gene KRT1 
and KRT10 are involved in hyper proliferative activity of cholesteatoma.197 Our 
proteomic results showed that WT HMGA2 interacted with KRT10 Keratin, Type I 
Cytoskeletal 10 (KRT10) which belongs to the intermediate filament proteins. In ovarian 
cancer, overexpression of KRT10 has been associated with improve the cisplatin-
resistance therapy by targeting PTEN in vitro198 and in vivo.199 
Preliminary in vivo studies targeting HMGA2 with camalexin, a natural product, 
suggests that high doses (100 mg/kg) is toxic and causes ulcerations. However, lower 
doses could decrease HMGA expression in ARCaP-M cells without affecting tumor 
growth. ARCaP-M cells express cytoplasmic/nuclear HMGA2 and mostly wild-type 
isoform; they are mesenchymal and metastatic, and since we have shown that the wild-
type HMGA2 promotes EMT but not cell viability, it is plausible that camalexin may not 













 High Mobility Group A2 (HMGA2) is a transcription factor that is highly 
expressed in early childhood and down-regulated in adulthood. Evidence has shown that 
HMGA2 is up-regulated in several cancers. Cancer patients overexpress two isoforms of 
HMGA2: wild-type (WT) and truncated (TR). We show that HMGA2 expression 
increases with prostate cancer progression. Overexpression WT HMGA2 in LNCaP 
prostate cancer cells show nuclear localization of the protein and induces EMT and cell 
migration via the MAPK pathway (see Figure 19).TR HMGA2 displays cytoplasmic 
expression and overexpression of this isoform increases cell proliferation significantly. 
Additionally, TR HMGA2 increases prostate cancer cell migration via increasing ROS 
and Jun-D (see Figure 19).  Finally, we show that a natural product, camalexin, may be a 

























Cancer Cell Tables 
 
Table A1. Prostate Cancer Cell Lines  
Parental and    
Transfectant    
Cell Lines Classifications Cell Line Derivatives Origin 
RWPE1 
 
Normal  Epithelial 
prostate cells 
RWPE1 Epithelial cells derived from peripheral 
zone  of histologically normal adult 
human prostate were transfected with 
single copy of the human 
poaoillomavirus 
 
LNCaP Androgen sensitive, 
adenocarcinoma 
LNCaP-Neo, LNCaP-
HMGA2 WT, HMGA2 
TR 
 
50-yr Caucasian male, left 
supraclavicular lymph node metastasis 
C4-2 Androgen independent 
and sensitive 
C4-2 parental Generated after a co-injection of 
LNCaP cells with human bone 
fibroblast in immunocompromised 
mice for 4 weeks followed by co-
injecting C4 cells in castrated host for 4 
weeks and harvesting the tumors. 
 
ARCaP Androgen repressed ARCaP-E, ARCaP-M. Derived from the ascites fluid of an 83-
year-old Caucasian man diagnosed with 
metastatic carcinoma of the prostate.  
 
E006AA Androgen-dependent E006AA-hT Africa-American prostate cancer cell 
line. Established as a spontaneously 
immortalized cells from a patient with a 
clinically localized prostate cancer. 
E006AA-ht Highly tumorigenic subline 
of E006AA Africa-American prostate 




Androgen independent  Cell established from bone metastasis 
grade IV of  prostate cancer in 62-year-
old Caucasian male 
 
 




Parental and    
Transfectant    
Cell Lines Classifications Cell Line Derivatives Origin 
MDA PCa  Androgen-independent 
adenocarcinoma of the 
prostate. 
MDA PCa 2a 
MDA PCa 2b 
MDA PCa 2b was established from a 
bone metastasis of 63 year old Black 
male with. 
 
Cells from this cell line produce tumors 
in nude mice when injected either 
subcutaneously or orthotopically 
(intraprostatic). 
 
This cell line is suitable for studying 
cell growth regulation by androgens. 
 
Table A2. Breast Cancer Cell Lines 
Parental and  Known  
Transfectant  Expression  
Cell lines Classifications Characteristics Origin 
MCF-7 Adenocarcinoma, 
epithelial, luminal A 











HMGA2 Supplemental Tables 
 
 
Table 1B. HMGA2 WT Co-immunoprecipitation  
    # # Unique # 
Accession Description Score Coverage Proteins Peptides Peptides 
P13645 Keratin, type I cytoskeletal 10 OS=Homo 
sapiens GN=KRT10 PE=1 SV=6 - 
[K1C10_HUMAN] 
110.65 3.08 25 2 2 
P04264 Keratin, type II cytoskeletal 1 OS=Homo 
sapiens GN=KRT1 PE=1 SV=6 - 
[K2C1_HUMAN] 
59.90 2.64   2 2 2 
E5RGW4 Nucleophosmin (Fragment) OS=Homo sapiens 
GN=NPM1 PE=1 SV=1 - 
[E5RGW4_HUMAN] 
44.68 22.03   2 1 1 
J3KMX5 40S ribosomal protein S13 OS=Homo sapiens 
GN=RPS13 PE=1 SV=1 - [J3KMX5_HUMAN] 
39.12 8.11   2 1 1 
Accession Description # PSMs # AAs MW [kDa] calc. pI 
P13645 Keratin, type I cytoskeletal 10 OS=Homo 
sapiens GN=KRT10 PE=1 SV=6 - 
[K1C10_HUMAN] 
8 584 58.8   5.21 
P04264 Keratin, type II cytoskeletal 1 OS=Homo 
sapiens GN=KRT1 PE=1 SV=6 - 
[K2C1_HUMAN] 
2 644 66.0   8.12 
E5RGW4 Nucleophosmin (Fragment) OS=Homo sapiens 
GN=NPM1 PE=1 SV=1 - 
[E5RGW4_HUMAN] 
1   59   6.9   4.48 
J3KMX5 40S ribosomal protein S13 OS=Homo sapiens 
GN=RPS13 PE=1 SV=1 - [J3KMX5_HUMAN] 







Table 2B. HMGA2 TR Co-immunoprecipitation  
 
               Continued
     
# Unique # 
Accession Description Score Coverage Proteins Peptides Peptides 
P60709 Actin, cytoplasmic 1 OS=Homo sapiens 
GN=ACTB PE=1 SV=1 - 
[ACTB_HUMAN] 
1052.46 24.00 24   7   7 
Q00610 Clathrin heavy chain 1 OS=Homo sapiens 
GN=CLTC PE=1 SV=5 - 
[CLH1_HUMAN] 
  595.80   9.43   5 11 11 
P11021 78 kDa glucose-regulated protein 
OS=Homo sapiens GN=HSPA5 PE=1 
SV=2 - [GRP78_HUMAN] 
  368.41 16.06   4   6   7 
P38646 Stress-70 protein, mitochondrial OS=Homo 
sapiens GN=HSPA9 PE=1 SV=2 - 
[GRP75_HUMAN] 
  331.31   6.33   2   3   3 
P38646 Stress-70 protein, mitochondrial OS=Homo 
sapiens GN=HSPA9 PE=1 SV=2 - 
[GRP75_HUMAN] 
  331.31   6.33   2   3   3 
P62269 40S ribosomal protein S18 OS=Homo 
sapiens GN=RPS18 PE=1 SV=3 - 
[RS18_HUMAN] 
  321.76 11.18   2   2   2 
E9PPU1 40S ribosomal protein S3 OS=Homo 
sapiens GN=RPS3 PE=1 SV=1 - 
[E9PPU1_HUMAN] 
  286.75 26.58 13   4   4 
P13645 Keratin, type I cytoskeletal 10 OS=Homo 
sapiens GN=KRT10 PE=1 SV=6 - 
[K1C10_HUMAN] 
  282.82   7.88 27   4   4 
E9PKE3 Heat shock cognate 71 kDa protein 
OS=Homo sapiens GN=HSPA8 PE=1 
SV=1 - [E9PKE3_HUMAN] 
  240.38 12.12   9   3   4 
Q1JUQ3 FK506 binding protein12 OS=Homo 
sapiens GN=FKBP12-Exin PE=2 SV=1 - 
[Q1JUQ3_HUMAN] 
  220.32 35.14   5   1   1 
A0A087WVQ9 Elongation factor 1-alpha 1 OS=Homo 
sapiens GN=EEF1A1 PE=4 SV=1 - 
[A0A087WVQ9_HUMAN] 
  217.89   5.22   6   1   2 
P04264 Keratin, type II cytoskeletal 1 OS=Homo 
sapiens GN=KRT1 PE=1 SV=6 - 
[K2C1_HUMAN] 
  215.22   7.30   3   5   5 
K7ELX4 Ferrochelatase, mitochondrial (Fragment) 
OS=Homo sapiens GN=FECH PE=1 SV=1 
- [K7ELX4_HUMAN] 
  163.63   6.44   2   2   2 
Q96HY3 CALM1 protein OS=Homo sapiens 
GN=CALM3 PE=1 SV=1 - 
[Q96HY3_HUMAN] 
  152.61 30.09   7   2   2 
Q05639 Elongation factor 1-alpha 2 OS=Homo 
sapiens GN=EEF1A2 PE=1 SV=1 - 
[EF1A2_HUMAN] 






                Continued 
     
# Unique # 
Accession Description Score Coverage Proteins Peptides Peptides 
J3KT73 60S ribosomal protein L38 OS=Homo 
sapiens GN=RPL38 PE=1 SV=1 - 
[J3KT73_HUMAN] 
136.47 35.94   4   2   2 
A0A075B6Z2 Protein TRAJ56 (Fragment) OS=Homo 
sapiens GN=TRAJ56 PE=4 SV=1 - 
[A0A075B6Z2_HUMAN] 
117.23 38.10   1   1   1 
M0QZL1 Flavin reductase (NADPH) OS=Homo 
sapiens GN=BLVRB PE=1 SV=1 - 
[M0QZL1_HUMAN] 
114.98   9.74   3   1   1 
P46783 40S ribosomal protein S10 OS=Homo 
sapiens GN=RPS10 PE=1 SV=1 - 
[RS10_HUMAN] 
113.02   5.45   3   1   1 
F8WF65 Elongation factor 1-beta OS=Homo sapiens 
GN=EEF1B2 PE=1 SV=1 - 
[F8WF65_HUMAN] 
111.22 51.72   4   1   1 
F8VVB9 Tubulin alpha-1B chain (Fragment) 
OS=Homo sapiens GN=TUBA1B PE=4 
SV=3 - [F8VVB9_HUMAN] 
100.28   9.31 13   2   2 
P62937 Peptidyl-prolyl cis-trans isomerase A 
OS=Homo sapiens GN=PPIA PE=1 SV=2 - 
[PPIA_HUMAN] 
  90.64 12.12   3   2   2 
H0YAB8 Transforming growth factor-beta-induced 
protein ig-h3 (Fragment) OS=Homo sapiens 
GN=TGFBI PE=4 SV=1 - 
[H0YAB8_HUMAN] 
  82.57 35.59   1   1   1 
P14174 Macrophage migration inhibitory factor 
OS=Homo sapiens GN=MIF PE=1 SV=4 - 
[MIF_HUMAN] 
  81.22   9.57   1   1   1 
P10809 60 kDa heat shock protein, mitochondrial 
OS=Homo sapiens GN=HSPD1 PE=1 
SV=2 - [CH60_HUMAN] 
  78.11   3.14   1   1   1 
P62851 40S ribosomal protein S25 OS=Homo 
sapiens GN=RPS25 PE=1 SV=1 - 
[RS25_HUMAN] 
  76.56 16.80   1   2   2 
B8ZZ54 10 kDa heat shock protein, mitochondrial 
OS=Homo sapiens GN=HSPE1 PE=1 
SV=1 - [B8ZZ54_HUMAN] 
  76.32 25.53   2   1   1 
I7HJJ0 ADP/ATP translocase 3 (Fragment) 
OS=Homo sapiens GN=SLC25A6 PE=1 
SV=1 - [I7HJJ0_HUMAN] 
  70.62   7.59   6   1    1 
M0R2L9 40S ribosomal protein S19 (Fragment) 
OS=Homo sapiens GN=RPS19 PE=1 SV=1 
- [M0R2L9_HUMAN] 
  67.54 18.31   5   1   1 
F5H2D2 Prohibitin-2 OS=Homo sapiens GN=PHB2 
PE=1 SV=1 - [F5H2D2_HUMAN] 
  67.45 19.54   6   1   1 
E7EPL9 Peroxisomal multifunctional enzyme type 2 
OS=Homo sapiens GN=HSD17B4 PE=1 
SV=1 - [E7EPL9_HUMAN] 






                Continued
     
# Unique # 
Accession Description Score Coverage Proteins Peptides Peptides 
Q9UM54 Unconventional myosin-VI OS=Homo 
sapiens GN=MYO6 PE=1 SV=4 - 
[MYO6_HUMAN] 
60.37   1.00 2 1 1 
Q13283 Ras GTPase-activating protein-binding 
protein 1 OS=Homo sapiens GN=G3BP1 
PE=1 SV=1 - [G3BP1_HUMAN] 
54.00   2.79 1 1 1 
E5RIP1 40S ribosomal protein S20 OS=Homo 
sapiens GN=RPS20 PE=1 SV=1 - 
[E5RIP1_HUMAN] 
50.79 23.91 3 1 1 
P19105 Myosin regulatory light chain 12A 
OS=Homo sapiens GN=MYL12A PE=1 
SV=2 - [ML12A_HUMAN] 
50.75   5.85 3 1 1 
A0A087WXI2 IgGFc-binding protein OS=Homo sapiens 
GN=FCGBP PE=4 SV=1 - 
[A0A087WXI2_HUMAN] 
50.37   0.29 2 1 1 
B1AN99 Trypsin-3 (Fragment) OS=Homo sapiens 
GN=PRSS3 PE=3 SV=3 - 
[B1AN99_HUMAN] 
50.13   7.30 2 1 1 
J3QKT4 Pyrroline-5-carboxylate reductase 
(Fragment) OS=Homo sapiens GN=PYCR1 
PE=1 SV=1 - [J3QKT4_HUMAN] 
49.05   9.50 4 1 1 
O95881 Thioredoxin domain-containing protein 12 
OS=Homo sapiens GN=TXNDC12 PE=1 
SV=1 - [TXD12_HUMAN] 
48.49   7.56 1 1 1 
O95373 Importin-7 OS=Homo sapiens GN=IPO7 
PE=1 SV=1 - [IPO7_HUMAN] 
48.14   2.12 1 1 1 
F8WE04 Heat shock protein beta-1 OS=Homo 
sapiens GN=HSPB1 PE=1 SV=1 - 
[F8WE04_HUMAN] 
46.71   5.38 2 1 1 
H0YIV0 Endoplasmin (Fragment) OS=Homo 
sapiens GN=HSP90B1 PE=1 SV=1 - 
[H0YIV0_HUMAN] 
44.47 10.88 2 1 1 
H0YB22 40S ribosomal protein S14 (Fragment) 
OS=Homo sapiens GN=RPS14 PE=1 SV=1 
- [H0YB22_HUMAN] 
43.26 15.00 3 1 1 
P62857 40S ribosomal protein S28 OS=Homo 
sapiens GN=RPS28 PE=1 SV=1 - 
[RS28_HUMAN] 
41.92 17.39 1 1 1 
P35579 Myosin-9 OS=Homo sapiens GN=MYH9 
PE=1 SV=4 - [MYH9_HUMAN] 
40.30   1.07 1 1 1 
Q5ST81 Tubulin beta chain OS=Homo sapiens 
GN=TUBB PE=1 SV=1 - 
[Q5ST81_HUMAN] 
40.24   2.42 5 1 1 
K7ES05 KN motif and ankyrin repeat domain-
containing protein 2 (Fragment) OS=Homo 
sapiens GN=KANK2 PE=1 SV=3 - 
[K7ES05_HUMAN] 





                Continued 
     
# Unique # 
Accession Description Score Coverage Proteins Peptides Peptides 
P01857 Ig gamma-1 chain C region OS=Homo 
sapiens GN=IGHG1 PE=1 SV=1 - 
[IGHG1_HUMAN] 
34.50   2.42 11   1   1 
Q9NPC6 Myozenin-2 OS=Homo sapiens 
GN=MYOZ2 PE=1 SV=1 - 
[MYOZ2_HUMAN] 
34.31   1.89   5   1   1 
Q8NC51 Plasminogen activator inhibitor 1 RNA-
binding protein OS=Homo sapiens 
GN=SERBP1 PE=1 SV=2 - 
[PAIRB_HUMAN] 
26.78   3.92   1   1   1 
M0QX76 40S ribosomal protein S16 (Fragment) 
OS=Homo sapiens GN=RPS16 PE=1 SV=1 
- [M0QX76_HUMAN] 
23.38 20.00   6   1   1 
Accession Description # PSMs # AAs MW [kDa] calc. pI 
P60709 Actin, cytoplasmic 1 OS=Homo sapiens 
GN=ACTB PE=1 SV=1 - 
[ACTB_HUMAN] 
42   375   41.7   5.48 
Q00610 Clathrin heavy chain 1 OS=Homo sapiens 
GN=CLTC PE=1 SV=5 - 
[CLH1_HUMAN] 
27 1675 191.5   5.69 
P11021 78 kDa glucose-regulated protein 
OS=Homo sapiens GN=HSPA5 PE=1 
SV=2 - [GRP78_HUMAN] 
17   654   72.3   5.16 
P38646 Stress-70 protein, mitochondrial OS=Homo 
sapiens GN=HSPA9 PE=1 SV=2 - 
[GRP75_HUMAN] 
  9   679   73.6   6.16 
P62269 40S ribosomal protein S18 OS=Homo 
sapiens GN=RPS18 PE=1 SV=3 - 
[RS18_HUMAN] 
15   152   17.7 10.99 
E9PPU1 40S ribosomal protein S3 OS=Homo 
sapiens GN=RPS3 PE=1 SV=1 - 
[E9PPU1_HUMAN] 
12   158   17.4   9.50 
P13645 Keratin, type I cytoskeletal 10 OS=Homo 
sapiens GN=KRT10 PE=1 SV=6 - 
[K1C10_HUMAN] 
17   584   58.8   5.21 
E9PKE3 Heat shock cognate 71 kDa protein 
OS=Homo sapiens GN=HSPA8 PE=1 
SV=1 - [E9PKE3_HUMAN] 
  7   627   68.8   5.52 
Q1JUQ3 FK506 binding protein12 OS=Homo 
sapiens GN=FKBP12-Exin PE=2 SV=1 - 
[Q1JUQ3_HUMAN] 
  6    37    4.0   5.78 
A0A087WVQ9 Elongation factor 1-alpha 1 OS=Homo 
sapiens GN=EEF1A1 PE=4 SV=1 - 
[A0A087WVQ9_HUMAN] 
  6   441   47.9   9.03 
P04264 Keratin, type II cytoskeletal 1 OS=Homo 
sapiens GN=KRT1 PE=1 SV=6 - 
[K2C1_HUMAN] 





                Continued 
 
 
Accession Description # PSMs # AAs MW [kDa] calc. pI 
K7ELX4 Ferrochelatase, mitochondrial (Fragment) 
OS=Homo sapiens GN=FECH PE=1 SV=1 
- [K7ELX4_HUMAN] 
  9 326 37.0   9.31 
Q96HY3 CALM1 protein OS=Homo sapiens 
GN=CALM3 PE=1 SV=1 - 
[Q96HY3_HUMAN] 
  5 113 12.9   4.26 
Q05639 Elongation factor 1-alpha 2 OS=Homo 
sapiens GN=EEF1A2 PE=1 SV=1 - 
[EF1A2_HUMAN] 
  5 463 50.4   9.03 
J3KT73 60S ribosomal protein L38 OS=Homo 
sapiens GN=RPL38 PE=1 SV=1 - 
[J3KT73_HUMAN] 
  7   64   7.6  9.99 
A0A075B6Z2 Protein TRAJ56 (Fragment) OS=Homo 
sapiens GN=TRAJ56 PE=4 SV=1 - 
[A0A075B6Z2_HUMAN] 
25   21   2.2 10.29 
M0QZL1 Flavin reductase (NADPH) OS=Homo 
sapiens GN=BLVRB PE=1 SV=1 - 
[M0QZL1_HUMAN] 
  4 154 15.7   5.45 
P46783 40S ribosomal protein S10 OS=Homo 
sapiens GN=RPS10 PE=1 SV=1 - 
[RS10_HUMAN] 
  4 165 18.9 10.15 
F8WF65 Elongation factor 1-beta OS=Homo sapiens 
GN=EEF1B2 PE=1 SV=1 - 
[F8WF65_HUMAN] 
  1   29   3.1   4.46 
F8VVB9 Tubulin alpha-1B chain (Fragment) 
OS=Homo sapiens GN=TUBA1B PE=4 
SV=3 - [F8VVB9_HUMAN] 
  3 247 27.5   5.20 
P62937 Peptidyl-prolyl cis-trans isomerase A 
OS=Homo sapiens GN=PPIA PE=1 SV=2 - 
[PPIA_HUMAN] 
  3 165 18.0   7.81 
H0YAB8 Transforming growth factor-beta-induced 
protein ig-h3 (Fragment) OS=Homo sapiens 
GN=TGFBI PE=4 SV=1 - 
[H0YAB8_HUMAN] 
  2   59   6.3   6.93 
P14174 Macrophage migration inhibitory factor 
OS=Homo sapiens GN=MIF PE=1 SV=4 - 
[MIF_HUMAN] 
  3 115 12.5   7.88 
P10809 60 kDa heat shock protein, mitochondrial 
OS=Homo sapiens GN=HSPD1 PE=1 
SV=2 - [CH60_HUMAN] 
  2 573 61.0   5.87 
P62851 40S ribosomal protein S25 OS=Homo 
sapiens GN=RPS25 PE=1 SV=1 - 
[RS25_HUMAN] 
  2 125 13.7 10.11 
B8ZZ54 10 kDa heat shock protein, mitochondrial 
OS=Homo sapiens GN=HSPE1 PE=1 
SV=1 - [B8ZZ54_HUMAN] 





               Continued 
 
Accession Description # PSMs # AAs MW [kDa] calc. pI 
I7HJJ0 ADP/ATP translocase 3 (Fragment) 
OS=Homo sapiens GN=SLC25A6 PE=1 
SV=1 - [I7HJJ0_HUMAN] 
  1   158 17.3   9.74 
M0R2L9 40S ribosomal protein S19 (Fragment) 
OS=Homo sapiens GN=RPS19 PE=1 SV=1 
- [M0R2L9_HUMAN] 
  1     71     8.2   8.88 
F5H2D2 Prohibitin-2 OS=Homo sapiens GN=PHB2 
PE=1 SV=1 - [F5H2D2_HUMAN] 
  2     87    9.3 10.24 
E7EPL9 Peroxisomal multifunctional enzyme type 2 
OS=Homo sapiens GN=HSD17B4 PE=1 
SV=1 - [E7EPL9_HUMAN] 
  1   474 51.0   8.38 
Q9UM54 Unconventional myosin-VI OS=Homo 
sapiens GN=MYO6 PE=1 SV=4 - 
[MYO6_HUMAN] 
  1 1294 149.6   8.53 
Q13283 Ras GTPase-activating protein-binding 
protein 1 OS=Homo sapiens GN=G3BP1 
PE=1 SV=1 - [G3BP1_HUMAN] 
  1   466 52.1   5.52 
E5RIP1 40S ribosomal protein S20 OS=Homo 
sapiens GN=RPS20 PE=1 SV=1 - 
[E5RIP1_HUMAN] 
  2     46   5.4   9.61 
P19105 Myosin regulatory light chain 12A 
OS=Homo sapiens GN=MYL12A PE=1 
SV=2 - [ML12A_HUMAN] 
  2   171   19.8   4.81 
A0A087WXI2 IgGFc-binding protein OS=Homo sapiens 
GN=FCGBP PE=4 SV=1 - 
[A0A087WXI2_HUMAN] 
  2 4204 444.9   5.35 
B1AN99 Trypsin-3 (Fragment) OS=Homo sapiens 
GN=PRSS3 PE=3 SV=3 - 
[B1AN99_HUMAN] 
  1   178 19.4   6.07 
J3QKT4 Pyrroline-5-carboxylate reductase 
(Fragment) OS=Homo sapiens GN=PYCR1 
PE=1 SV=1 - [J3QKT4_HUMAN] 
  1   242 25.6   6.61 
O95881 Thioredoxin domain-containing protein 12 
OS=Homo sapiens GN=TXNDC12 PE=1 
SV=1 - [TXD12_HUMAN] 
  3   172 19.2   5.40 
O95373 Importin-7 OS=Homo sapiens GN=IPO7 
PE=1 SV=1 - [IPO7_HUMAN] 
  1 1038 119.4   4.82 
F8WE04 Heat shock protein beta-1 OS=Homo 
sapiens GN=HSPB1 PE=1 SV=1 - 
[F8WE04_HUMAN] 
  1   186   20.4   9.06 
H0YIV0 Endoplasmin (Fragment) OS=Homo 
sapiens GN=HSP90B1 PE=1 SV=1 - 
[H0YIV0_HUMAN] 
  2   147   17.0   4.36 
H0YB22 40S ribosomal protein S14 (Fragment) 
OS=Homo sapiens GN=RPS14 PE=1 SV=1 
- [H0YB22_HUMAN] 






Table 3B. HMGA2 IgG Co-immunoprecipitation  
P60709 Actin, cytoplasmic 1 OS=Homo sapiens 
GN=ACTB PE=1 SV=1 - 
[ACTB_HUMAN] 
236.13 17.33 30 5 5 
G3V361 Calmodulin (Fragment) OS=Homo sapiens 
GN=CALM1 PE=1 SV=1 - 
[G3V361_HUMAN] 
94.74 21.43   7 2 2 
P62269 40S ribosomal protein S18 OS=Homo 
sapiens GN=RPS18 PE=1 SV=3 - 
[RS18_HUMAN] 
82.12 12.50   2 2 2 
K7EMD9 Keratin, type I cytoskeletal 13 (Fragment) 
OS=Homo sapiens GN=KRT13 PE=1 
SV=1 - [K7EMD9_HUMAN] 
76.16 4.24 25 1 1 
Q1JUQ3 FK506 binding protein12 OS=Homo 
sapiens GN=FKBP12-Exin PE=2 SV=1 - 
[Q1JUQ3_HUMAN] 
74.70 35.14   5 1 1 
 
               Continued 
 
Accession Description # PSMs # AAs MW [kDa] calc. pI 
P62857 40S ribosomal protein S28 OS=Homo 
sapiens GN=RPS28 PE=1 SV=1 - 
[RS28_HUMAN] 
  1     69    7.8 10.70 
P35579 Myosin-9 OS=Homo sapiens GN=MYH9 
PE=1 SV=4 - [MYH9_HUMAN] 
  1 1960 226.4   5.60 
Q5ST81 Tubulin beta chain OS=Homo sapiens 
GN=TUBB PE=1 SV=1 - 
[Q5ST81_HUMAN] 
  1   372   41.7   4.91 
K7ES05 KN motif and ankyrin repeat domain-
containing protein 2 (Fragment) OS=Homo 
sapiens GN=KANK2 PE=1 SV=3 - 
[K7ES05_HUMAN] 
  1 148 16.3 8.85 
P01857 Ig gamma-1 chain C region OS=Homo 
sapiens GN=IGHG1 PE=1 SV=1 - 
[IGHG1_HUMAN] 
  1 330 36.1 8.19 
Q9NPC6 Myozenin-2 OS=Homo sapiens 
GN=MYOZ2 PE=1 SV=1 - 
[MYOZ2_HUMAN] 
  1 264 29.9 8.25 
Q8NC51 Plasminogen activator inhibitor 1 RNA-
binding protein OS=Homo sapiens 
GN=SERBP1 PE=1 SV=2 - 
[PAIRB_HUMAN] 
  1 408 44.9 8.65 
M0QX76 40S ribosomal protein S16 (Fragment) 
OS=Homo sapiens GN=RPS16 PE=1 SV=1 
- [M0QX76_HUMAN] 
  1 50 5.6 9.63 
     
# Unique # 




P04264 Keratin, type II cytoskeletal 1 OS=Homo 
sapiens GN=KRT1 PE=1 SV=6 - 
[K2C1_HUMAN] 
66.80   1.40 1 1 1 
P81605 Dermcidin OS=Homo sapiens GN=DCD 
PE=1 SV=2 - [DCD_HUMAN] 
43.17 10.00 1 1 1 
A0A075B6Z2 Protein TRAJ56 (Fragment) OS=Homo 
sapiens GN=TRAJ56 PE=4 SV=1 - 
[A0A075B6Z2_HUMAN] 
40.45 38.10 1 1 1 
P60709 Actin, cytoplasmic 1 OS=Homo sapiens 
GN=ACTB PE=1 SV=1 - 
[ACTB_HUMAN] 
10 375 41.7 5.48 
G3V361 Calmodulin (Fragment) OS=Homo sapiens 
GN=CALM1 PE=1 SV=1 - 
[G3V361_HUMAN] 
5 98 11.1 4.25 
P62269 40S ribosomal protein S18 OS=Homo 
sapiens GN=RPS18 PE=1 SV=3 - 
[RS18_HUMAN] 
3 152 17.7 10.99 
K7EMD9 Keratin, type I cytoskeletal 13 (Fragment) 
OS=Homo sapiens GN=KRT13 PE=1 
SV=1 - [K7EMD9_HUMAN] 
5 165 19.2 4.74 
Q1JUQ3 FK506 binding protein12 OS=Homo 
sapiens GN=FKBP12-Exin PE=2 SV=1 - 
[Q1JUQ3_HUMAN] 
1 37 4.0 5.78 
P04264 Keratin, type II cytoskeletal 1 OS=Homo 
sapiens GN=KRT1 PE=1 SV=6 - 
[K2C1_HUMAN] 
2 644 66.0 8.12 
P81605 Dermcidin OS=Homo sapiens GN=DCD 
PE=1 SV=2 - [DCD_HUMAN] 
2 110 11.3 6.54 
A0A075B6Z2 Protein TRAJ56 (Fragment) OS=Homo 
sapiens GN=TRAJ56 PE=4 SV=1 - 
[A0A075B6Z2_HUMAN] 
7 21 2.2 10.29 
 
     
# Unique # 
Accession Description Score Coverage Proteins Peptides Peptides 
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